<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d2 20140930//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.0 20120330//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 39.96?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">Sarcoma</journal-id><journal-id journal-id-type="iso-abbrev">Sarcoma</journal-id><journal-id journal-id-type="publisher-id">SARCOMA</journal-id><journal-title-group><journal-title>Sarcoma</journal-title></journal-title-group><issn pub-type="ppub">1357-714X</issn><issn pub-type="epub">1369-1643</issn><publisher><publisher-name>Hindawi Publishing Corporation</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">4377510</article-id><article-id pub-id-type="doi">10.1155/2015/839182</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Molecular Analysis of a Recurrent Sarcoma Identifies a Mutation in FAF1</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Weber</surname><given-names>Georg F.</given-names></name><xref ref-type="aff" rid="I1"/><xref ref-type="corresp" rid="cor1"><sup>*</sup>
</xref></contrib></contrib-group><aff id="I1">College of Pharmacy, University of Cincinnati, 3225 Eden Avenue, Cincinnati, OH 45267-0004, USA</aff><author-notes><corresp id="cor1">*Georg F. Weber: <email>georg.weber@uc.edu</email></corresp><fn fn-type="other"><p>Academic Editor: Enrique de Alava</p></fn></author-notes><pub-date pub-type="ppub"><year>2015</year></pub-date><pub-date pub-type="epub"><day>10</day><month>3</month><year>2015</year></pub-date><volume>2015</volume><elocation-id>839182</elocation-id><history><date date-type="received"><day>18</day><month>11</month><year>2014</year></date><date date-type="accepted"><day>11</day><month>2</month><year>2015</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2015 Georg F. Weber.</copyright-statement><copyright-year>2015</copyright-year><license license-type="open-access"><license-p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>A patient presented with a recurrent sarcoma (diagnosed as leiomyosarcoma) 12 years after the removal of an initial cancer (diagnosed as extracompartmental osteosarcoma) distally on the same limb. Following surgery, the sarcoma and unaffected muscle and bone were subjected to measurements of DNA exome sequence, RNA and protein expression, and transcription factor binding. The investigation provided corroboration of the diagnosis leiomyosarcoma, as the major upregulations in this tumor comprise muscle-specific gene products and calcium-regulating molecules (calcium is an important second messenger in smooth muscle cells). A likely culprit for the disease is the point mutation S181G in FAF1, which may cause a loss of apoptotic function consecutive to transforming DNA damage. The RNA levels of genes for drug transport and metabolism were extensively skewed in the tumor tissue as compared to muscle and bone. The results suggest that the tumor represents a recurrence of a dormant metastasis from an originally misdiagnosed neoplasm. A loss of FAF1 function could cause constitutive WNT pathway activity (consistent with the downstream inductions of IGF2BP1 and E2F1 in this cancer). While the study has informed on drug transport and drug metabolism pharmacogenetics, it has fallen short of identifying a suitable target for molecular therapy.</p></abstract></article-meta></front><body><sec id="sec1"><title>1. Introduction</title><p>Sarcomas are cancers of mesenchymal origin [<xref rid="B1" ref-type="bibr">1</xref>] that comprise about 1% of adult malignancies. Leiomyosarcomas are derived from smooth muscle cells. At most primary sites, other than the uterus or gastrointestinal tract, leiomyosarcomas are likely to originate from the tunica media of blood vessels. However, it has been postulated that primary leiomyosarcoma of the bone might also develop through advanced myogenic metaplasia of a sarcoma originating from fibroblastic tissue [<xref rid="B2" ref-type="bibr">2</xref>]. The disease typically occurs in the 5th to 6th decades of life, with women being affected more than men (2&#x02009;:&#x02009;1). This gender distribution may reflect the proliferation of smooth muscle that can occur in response to estrogen [<xref rid="B3" ref-type="bibr">3</xref>].</p><p>Because sarcomas tend to respond poorly to standard chemotherapy, they have no good treatment options beside total excision with wide margins. However, the gradual replacement of the highly toxic conventional cancer chemotherapy (comprising nonspecific antiproliferative agents) with molecularly targeted drugs, which was initiated with the market entry of neutralizing antibodies and small molecule kinase inhibitors in 1997 (Rituxan) and 2001 (Gleevec), respectively, has opened the possibility to tailor drug treatment to particular tumors. Yet, this transition has also necessitated the molecular characterization of the lesions that are causative for the transformation of healthy cells to cancerous cells because drugs need to be matched with the underlying carcinogenic defect to be effective. Here, we take a sarcoma through a comprehensive molecular analysis that applies multiple screening techniques, with the goal to identify the disease-causing defects as well as potential drug targets.</p></sec><sec id="sec2"><title>2. Materials and Methods</title><sec id="sec2.1"><title>2.1. Patient and Tissues</title><p>A 52-year-old female patient underwent surgery for a recurrent sarcoma. Samples of skeletal muscle, bone, and tumor were obtained postsurgery.</p></sec><sec id="sec2.2"><title>2.2. DNA Exome Sequencing</title><p>1&#x02009;<italic>&#x003bc;</italic>g of dsDNA determined by Invitrogen Qubit high sensitivity spectrofluorometric measurement was sheared by sonication to an average size of 300&#x02009;bp on a Diagenode Bioruptor. Automated library construction was performed on an IntegenX Apollo324 which size-selects fragments by double-SPRI binding with different concentrations of PEG for a high cut and a low cut. Each library can be fitted with one of 48 adapters, each containing a different 6-base molecular barcode for high level multiplexing. After 12 cycles of PCR amplification, 1&#x02009;<italic>&#x003bc;</italic>g of genomic library was recovered for exome enrichment using the NimbleGen EZ Exome V2 kit. Enriched libraries were sequenced on an Illumina HiSeq2000, generating around 32 million high quality paired end reads of 100 base each or 6.4&#x02009;GB of usable sequence per sample. The analysis methods utilize the Broad Institute's Genome Analysis Toolkit (GATK) and follow a pipeline previously described [<xref rid="B4" ref-type="bibr">4</xref>], along with published modifications (<ext-link ext-link-type="uri" xlink:href="http://www.broadinstitute.org/gsa/wiki/index.php/The_Genome_Analysis_Toolkit">http://www.broadinstitute.org/gsa/wiki/index.php/The_Genome_Analysis_Toolkit</ext-link>). The analysis comprises aligning the reads that pass Illumina Chastity Filter with the Burrows-Wheeler Aligner (BWA) [<xref rid="B5" ref-type="bibr">5</xref>]. For each sample, Picard's MarkDuplicates are used to flag reads that appear to be artifacts of PCR bias. All reads that overlap known or putative indels are realigned. All base quality scores are recalibrated to the empirical error rate derived from nonpolymorphic sites. The GATK's Unified Genotyper module is used to call variant sites (both single nucleotide and small indel) in all samples simultaneously. Finally, the SNV calls are filtered using the variant quality score recalibration method [<xref rid="B4" ref-type="bibr">4</xref>]. Indel calls were filtered with a set of hard filters, as there are not enough indels in an exome to use the Gaussian method.</p></sec><sec id="sec2.3"><title>2.3. RNAseq</title><p>Tissue samples were homogenized in RNazol RT (MRC) with a manual homogenizer and stored on ice until extraction. The RNA isolation was performed according to the manufacturer's instructions.</p><p>The Ovation RNA-Seq FFPE system (NuGen) was used to initiate amplification at both 3&#x02032; end as well as randomly throughout the transcriptome in the sample. 100&#x02009;ng of total RNA with RIN &#x0003c; 5.0 was converted into a library of template molecules suitable for subsequent cluster generation and sequencing by Illumina HiSeq. Total RNA was reverse transcribed and converted to double stranded cDNA with a unique DNA/RNA heteroduplex at one end. NuGEN's Ribo-SPIA technology was used for isothermal amplification resulting in the rapid generation of cDNA with a sequence complementary to the original mRNA. The cDNA was then double stranded and fragmented to 200&#x02009;bp using Covaris S2, and a sequencing library was generated using Illumina's TruSeq DNA Sample Prep Kit V2 according to standard protocols. The cDNA library was enriched by a limited number of 10&#x02009;PCR cycles, validated using an Agilent 2100 Bioanalyzer, and quantitated using the Quant-iT dsDNA HS Kit (Invitrogen). Two individually indexed cDNA libraries were pooled and sequenced on Illumina HiSeq to get a minimum of 90 million reads. Libraries were clustered onto a flow cell using Illumina's TruSeq SR Cluster Kit v2.5 and sequenced 50 cycles using TruSeq SBS Kit-HS on HiSeq. The obtained sequence reads were aligned to the genome by using the standard Illumina sequence analysis pipeline.</p></sec><sec id="sec2.4"><title>2.4. Protein-DNA Array</title><p>Tissues were ground between frosted glass slides and then incubated with Collagenase and Dispase in cell culture medium at 37&#x000b0;C for 45 minutes to release individual cells. These cells were collected after passing the samples through a strainer and centrifugation. Nuclear extracts and cytosol were prepared using a kit from Active Motif. After protein determination, DNA binding of the nuclear extracts was assessed with the Combo protein-DNA array (Panomics). Signal intensity was measured with the software MetaMorph.</p></sec><sec id="sec2.5"><title>2.5. Western Blotting</title><p>For the analysis of individual proteins, tissues were homogenized in RIPA buffer (50&#x02009;mM Tris-HCl pH 7.5, 150&#x02009;mM NaCl, 1% NP-40, 0.1% sodium dodecyl sulfate) using a handheld, battery-operated homogenizer. 10&#x02009;<italic>&#x003bc;</italic>g lysates were loaded per lane and electrophoresed on 10% SDS-polyacrylamide minigels with reducing, denaturing sample buffer. The separated proteins were transferred to PVDF membranes and probed with antibody O-17 (IBC) to the C-terminus of osteopontin and anti-HCAM to the cytoplasmic domain of CD44 (Santa Cruz) and to STAT3 and phospho-STAT3 (Cell Signaling Technology). Antitubulin serves as a loading control.</p></sec><sec id="sec2.6"><title>2.6. 2D Gel Electrophoresis and Mass Spectrometry</title><p>The tumor and muscle samples were diluted to 4 and 1&#x02009;mg/mL in 1&#x02009;:&#x02009;1 diluted SDS Boiling Buffer&#x02009;:&#x02009;Urea Sample Buffer before loading (the bone sample was ethanol precipitated and redissolved to 4 and 1&#x02009;mg/mL in 1&#x02009;:&#x02009;1 diluted SDS Boiling Buffer&#x02009;:&#x02009;Urea Sample Buffer). Two-dimensional electrophoresis was performed according to the carrier ampholine method of isoelectric focusing [<xref rid="B6" ref-type="bibr">9</xref>, <xref rid="B7" ref-type="bibr">10</xref>] by Kendrick Labs, Inc. Isoelectric focusing was carried out in glass tubes of inner diameter 2.3&#x02009;mm using 2% pH 4&#x02013;8 Servalytes (Serva, Germany) for 9600 volt-hours. 1&#x02009;<italic>&#x003bc;</italic>g (Coomassie stain) or 50&#x02009;ng (silver stain) of an IEF internal standard, tropomyosin, was added to each sample. This protein migrates as a doublet with lower polypeptide spot of MW 33,000 and pI 5.2; its position is marked by an arrow on the stained gels. The enclosed tube gel pH gradient plot for this set of ampholines was determined with a surface pH electrode.</p><p>After equilibration for 10&#x02009;min in buffer &#x0201c;O&#x0201d; (10% glycerol, 50&#x02009;mm dithiothreitol, 2.3% SDS, and 0.0625&#x02009;M Tris, pH 6.8), each tube gel was sealed to the top of a stacking gel that was on top of a 10% acrylamide slab gels (0.75&#x02009;mm thick). SDS slab gel electrophoresis was carried out for about 4 hours at 15&#x02009;mA/gel. The following proteins (Sigma Chemical Co.) were used as molecular weight standards: myosin (220,000), phosphorylase A (94,000), catalase (60,000), actin (43,000), carbonic anhydrase (29,000), and lysozyme (14,000). These standards appear along the basic edge of the Coomassie blue R-250 stained or silver-stained [<xref rid="B8" ref-type="bibr">11</xref>] 10% acrylamide slab gel. The gels were dried between sheets of cellophane paper with the acid edge to the left. Each of the gels was overlaid with a transparent sheet for labeling polypeptide spot differences without marking the original gel (Kendrick Labs).</p></sec><sec id="sec2.7"><title>2.7. Polymorphism Analysis</title><p>We obtained 22 formalin-fixed, paraffin-embedded leiomyosarcoma specimens (stroma and paraffin had been removed from unstained slides under microscopic examination) through the Department of Pathology, University of Cincinnati. DNA was extracted with the AllPrep DNA/RNA FFPE kit (Qiagen). We purchased 7 frozen leiomyosarcoma tissues from Creative Bioarray and extracted DNA with the AllPrep DNA/RNA Mini Kit (Qiagen). One blood sample from a leiomyosarcoma patient was received from the University of Cincinnati Tissue Bank. Polymorphisms in FAF1 were analyzed in the DNA using a custom TaqMan assay with the probe ACACCAGATTTGCCACCACCTTCATCATCT [A/G] GTCATGCTGGGTAAGTTGTTTATATTTCCTG. A TaqMan assay with an existing probe for position &#x02212;443 in the osteopontin promoter served as a reference assay. 34 breast cancer DNA samples served as nonsarcoma control. The assay was performed by the CCHMC DNA core.</p></sec></sec><sec id="sec3"><title>3. Results</title><sec id="sec3.1"><title>3.1. Patient History</title><p>In 1998, the patient was diagnosed with high grade, stage IIb osteogenic sarcoma of the right femur, which was extracompartmental. Upon resection the lesion had a size of 9.5 &#x000d7; 3 &#x000d7; 4&#x02009;cm (<xref ref-type="fig" rid="fig1">Figure 1</xref>). The tumor was assessed as stage T2NxMx, grade III, characterized as hypercellular; it showed marked cytologic atypia and a high mitotic rate. Histologic features included anaplasia, pleomorphism, numerous abnormal mitoses, numerous giant cells, and osteoid production with focal calcifications.</p><p>In 2012, a CT scan, done because of hip pain, revealed a 4.3 &#x000d7; 3.4 &#x000d7; 3.1&#x02009;cm lytic mass in the superior right acetabulum, grossly stable in size and configuration. There was diffuse osteopenia involving the right femoral head and neck with diffuse atrophy of the right pelvic girdle musculature. Periostitis and cortical interruption were associated with this lesion.</p><p>The postsurgical pathology report identified the 5.7 &#x000d7; 5.5 &#x000d7; 4.9&#x02009;cm mass as a high grade leiomyosarcoma, stage pT2bpNx. Whereas a bone scan revealed intense activity in the left seventh rib, a follow-up chest CT provided no indication of pulmonary masses, mediastinal or hilar lymphadenopathy, enlargement of axillary nodes, or pleural effusion, implying stage M0. The mitotic rate was 70%, with 60% necrosis. The tumor caused extensive bone destruction and involvement of adjacent tissue. Histologically, the tumor cells stained positively for smooth muscle actin. They were also positive for CD68 and displayed diffuse positive staining for vimentin but were negative for CD117, pancreatin, S-100, and CD34.</p><p>Seven months after the surgery, the patient received a PET-MRI scan for pain, which revealed six metastatic lesions, including both lungs and multiple ribs. She was put on three 21-day cycles of Gemzar (days 1 and 8), Taxotere (day 8), and Neulasta (beginning on day 9) but was unable to continue past the first cycle due to hospitalizations for continued and problematic wound infections at the surgical lung biopsy sites.</p></sec><sec id="sec3.2"><title>3.2. DNA Exome Sequence</title><p>Exome sequencing of the genomic DNAs for tumor, muscle, and bone identified 65546 potential sequence variants. Filtering yielded 46 likely somatic mutations in the tumor (<xref ref-type="table" rid="tab1">Table 1</xref>), of which 7 (affecting EIF4A1, EPHA3, FAF1, IPO8, KIAA1377, LIMCH1, and NIPBL) were confirmed in the RNASeq results. FAF1 associates with FAS and enhances apoptosis mediated through this receptor [<xref rid="B9" ref-type="bibr">12</xref>]. The point mutation S181G (<xref ref-type="fig" rid="fig2">Figure 2</xref>) could cause a loss of function in FAF1 and lead to transformation via antiapoptosis.</p></sec><sec id="sec3.3"><title>3.3. RNA Analysis</title><p>Expectedly, the gene expression patterns, according to RNASeq, were very different among tumor, muscle, and bone. The cancer contained several gene products that were overexpressed compared to both muscle and bone (Tables <xref ref-type="table" rid="tab2">2</xref>(a) and <xref ref-type="table" rid="tab2">2</xref>(b)). Among the top 30 changes in the tumor/muscle and tumor/bone comparisons, 13 were identical (<xref ref-type="table" rid="tab2">Table 2(c)</xref>). It is implied that these gene products are quite unique for the tumor and likely contribute to its pathogenesis. This notion is supported by the upregulation of the smooth muscle gene Ano4, which corroborates the leiomyosarcomatous nature of the cancer. When limiting the analysis to genes expressed at least at the level of 1 unit, the 17 genes overexpressed in the tumor/muscle and tumor/bone comparisons contain several extracellular matrix proteins, implying an active remodeling of the tumor microenvironment (<xref ref-type="table" rid="tab2">Table 2(d)</xref>). By contrast, none of the underexpressed gene products in the tumor/muscle comparison matched the tumor/bone comparison (not shown).</p><p>Of note, the RNA level of IGF2BP1 (IMP-1, CRD-BP, and ZBP-1) is highly upregulated in the tumor compared to muscle as well as bone. IGF2BP1 is a RNA-binding factor that affects mRNA nuclear export, localization, stability, and translation. It regulates mRNA stability during the integrated cellular stress response in stress granules. IGF2BP1 is a transcriptional target of the WNT pathway, which is negatively regulated by intact FAF1 and may be unregulated by FAF1<sup>S181G</sup>. The IGF system has been linked to sarcoma pathogenesis [<xref rid="B10" ref-type="bibr">13</xref>] and may play a role in this specific cancer. Other IGF family members with increased RNA message levels in this tumor (compared to muscle and bone) include IGFBPL1 (5-6-log<sub>2</sub>-fold), IGFL3 (6-7-log<sub>2</sub>-fold), and IGF2BP3 (2-6-log<sub>2</sub>-fold).</p><p>The identified point mutation in FAF1 may be pathogenetic for this cancer. FAF1 is a regulator of NF-<italic>&#x003ba;</italic>B activation. It directly binds to RelA (P65), retaining it in the cytoplasm. It can also interact with IKK<italic>&#x003b2;</italic>, thus allowing for the I<italic>&#x003ba;</italic>B-mediated degradation of the transcription factors P65 and P50 [<xref rid="B11" ref-type="bibr">6</xref>]. Consistently, the expression of regulators of the NF-<italic>&#x003ba;</italic>B activation pathway is skewed in the tumor compared to muscle or bone (<xref ref-type="table" rid="tab2">Table 2(e)</xref>).</p></sec><sec id="sec3.4"><title>3.4. Transcription Factor Binding</title><p>Protein/DNA arrays measure the binding activity of transcription factors. They comprise three basic steps. A set of biotin-labeled DNA binding oligonucleotides are preincubated with a nuclear extract of interest. The protein/DNA complexes are separated from the free probes. The probes in the complexes are then extracted and hybridized to prespotted membranes followed by HRP-based chemiluminescence detection. We made nuclear extracts from tumor, bone, and muscle and tested them for DNA binding activity. Binding that was induced in cancer, but not in the normal tissues, was displayed by the transcription factors E2F1, AP3, LIII-BP, PAX6, ADD-1, and CCAC [<xref rid="B32" ref-type="bibr">14</xref>&#x02013;<xref rid="B37" ref-type="bibr">19</xref>]. The CCAC binding activity is consistent with a muscle-derived tumor. E2F1 may associate with the WNT pathway-induced transcription factor LEF1, resulting in transcriptional derepression of E2F1 [<xref rid="B12" ref-type="bibr">20</xref>]. Likely constitutive transcription factors that are active in all 3 tissues comprise AhR/Amt, GATA1, GATA2, GATA1/2, HIF1, and HOXD8/9/10 (<xref ref-type="fig" rid="fig3">Figure 3</xref>).</p></sec><sec id="sec3.5"><title>3.5. Protein Analysis</title><p>2D gel electrophoresis of the RIPA lysates from tumor, muscle, and bone showed very divergent patterns (<xref ref-type="fig" rid="fig4">Figure 4(a)</xref>). Two experienced analysts compared the protein pattern from the tumor with the protein pattern from either bone or muscle. Polypeptide spots that were unique to the gels from the tumor were outlined (spots unique to or relatively darker in the bone or muscle were not indicated). The labeled proteins were extracted for identification with mass spectrometry. This yielded several structural proteins, which may reflect modification of the cellular architecture under rapid growth. Transgelin-1 and transgelin-2 were abundant and corroborated the identity of the tumor as a leiomyosarcoma. Four calcium-binding proteins were highly expressed in the cancer. In addition, regulators of protein synthesis (40S ribosomal protein S12, glycine-tRNA ligase), protein modification (N-terminal fragment of heat shock protein HSP 90<italic>&#x003b1;</italic>, C-terminal fragment of protein disulfide isomerase), and protein degradation (<italic>&#x003b1;</italic>1-antitrypsin, proteasome activator complex subunit 2) were identified (<xref ref-type="fig" rid="fig4">Figure 4(b)</xref>). Of interest may be the C-terminal fragment of protein disulfide isomerase, which not only hydroxylates prolines in preprocollagen but also contributes to microsomal triglyceride transfer. It could be reflective of a skewed tumor metabolism. The protein analysis was corroborated by the mRNA levels (<xref ref-type="fig" rid="fig4">Figure 4(d)</xref>).</p><p>Cancer markers were tested according to Western blot (<xref ref-type="fig" rid="fig4">Figure 4(c)</xref>). The tumor, but not normal muscle, expressed the metastasis protein osteopontin and a single small form (&#x0003c;75&#x02009;kD) of CD44 that is likely the not alternatively spliced, standard form. Unexpectedly, while both tumor and muscle expressed comparably abundant amounts of STAT3, phosphorylation (reflective of activation) was present in the muscle but not in the tumor. The STAT3 pathway is associated with progression in several human cancers, and this is often reflected in STAT3 constitutive phosphorylation. The lack of phosphorylation in this case suggests that the leiomyosarcoma may not depend on the STAT3 pathway.</p></sec><sec id="sec3.6"><title>3.6. Pharmacogenetic Evaluation</title><p>Predicting the sensitivity to anticancer drugs is a main goal of molecular analysis. For this, the over- or underexpression of genes for drug transport and metabolism is of key importance. Analysis of the RNASeq data for these groups of gene products identified a surprisingly large number of deregulations compared to muscle or bone (Tables <xref ref-type="table" rid="tab3">3</xref>(a) and <xref ref-type="table" rid="tab3">3</xref>(b)). Those alterations may affect choices for drug treatment. For example, the high levels of glutathione S-transferase may render carmustine, thioTEPA, cisplatin, chlorambucil, melphalan, nitrogen mustard, phosphoramide mustard, acrolein, or steroids ineffective. The overexpression of<italic> N</italic>-acetyltransferase may compromise 5-fluorouracil or taxol. The modest upregulation of only two export transporters (ABC-transporters), and specifically the lack of ABCB1 overexpression, is favorable for avoiding drug resistance.</p></sec><sec id="sec3.7"><title>3.7. Population Analysis</title><p>The above-described results indicated that a FAF1 mutation, which replaces serine in position 181, thus preventing FAF1 phosphorylation and activation, may be a driver for leiomyosarcomagenesis. A custom TaqMan assay confirmed the presence of the somatic mutation in the patient. To assess whether this single nucleotide replacement is common in this type of cancer, we analyzed DNA from 29 leiomyosarcomas and 1 blood sample from a leiomyosarcoma patient. For comparison to nonsarcomatous tumors, 34 breast cancers served as a reference. None of them displayed a mutation in the same locus. By contrast, there was a distribution across all leiomyosarcomas in the osteopontin promoter position &#x02212;443 (used as a reference), with 12 CC, 10 TC, and 9 TT.</p></sec></sec><sec id="sec4"><title>4. Discussion</title><p>The FAF1 mutation identified as the likely cause for the cancer under study gives room for an explanation of the sarcomatous transformation (<xref ref-type="fig" rid="fig5">Figure 5</xref>). DNA damage to mesenchymal cells occurs persistently in an oxidizing environment at 37&#x000b0;C. These insults are rarely transforming, and such an occurrence would trigger the initiation of programmed cell death in apoptosis-competent cells. Intact FAF1 associates with FAS and enhances apoptosis mediated through this receptor [<xref rid="B9" ref-type="bibr">12</xref>]. A loss of function in FAF1 could lead to transformation via antiapoptosis. Whereas the mutation S181G is not expected to disrupt the structure of the protein, this site does score high as a possible phosphorylation site for a number of kinases involved in DNA damage repair, supporting the hypothesis that the cancer cells containing this mutation have lost their ability to respond to transforming DNA damage with programmed cell death. FAF1 antagonizes WNT signaling by promoting <italic>&#x003b2;</italic>-catenin degradation in the proteasome [<xref rid="B13" ref-type="bibr">21</xref>], a function that may be lost after the point mutation. The elevated DNA binding activity of the protooncogenic transcription factor E2F1 (see <xref ref-type="fig" rid="fig3">Figure 3</xref>) could be caused by its interaction with LEF-1 [<xref rid="B12" ref-type="bibr">20</xref>], consecutive to persistent WNT signaling. The RNA level of IGF2BP1 (IMP-1), a stress-responsive regulator of mRNA stability, is highly upregulated in the tumor compared to muscle as well as bone (see <xref ref-type="table" rid="tab2">Table 2(c)</xref>). IGF2BP1 is a transcriptional target of the WNT pathway that regulates NF-<italic>&#x003ba;</italic>B activity (see <xref ref-type="table" rid="tab2">Table 2(e)</xref>) and is antiapoptotic [<xref rid="B14" ref-type="bibr">22</xref>, <xref rid="B15" ref-type="bibr">23</xref>]. IGF2BP1 may be upregulated as a consequence of mutated FAF1 not being able to suppress WNT signaling in this specific cancer. Of note, WNT pathway overactivity may not be required for transformation; rather the persistence of a WNT pathway signal due to the lack of a FAF1-mediated termination signal may suffice.</p><p>The role of WNT signaling in sarcoma has been subject to debate (e.g., [<xref rid="B16" ref-type="bibr">24</xref>]). In metastatic leiomyosarcoma, <italic>&#x003b2;</italic>-Catenin may accumulate in the nucleus despite a relatively weak expression of WNT [<xref rid="B17" ref-type="bibr">25</xref>]. This may be due to WNT signal activation via noncanonical ligands [<xref rid="B18" ref-type="bibr">26</xref>] or to <italic>&#x003b2;</italic>-Catenin binding the nuclear receptor NR4A2 and releasing it from the corepressor protein LEF-1 [<xref rid="B19" ref-type="bibr">27</xref>]. Of note, in the cancer under study here, the mRNA level of NR4A2 was overexpressed 10-fold compared to bone and 3-fold compared to muscle. The results from this study are consistent with the possibility that a lack of termination in the WNT signal, rather than its overactivation, could contribute to sarcomatous transformation. Such a mechanism may be reflected in an upregulation of downstream targets, even though overexpression of WNT pathway components is not detectable.</p><p>Other mutations, beside FAF1, are less likely to be causative for the cancer. EPHA3 was revealed as mutated in this cancer by DNA exome sequencing and RNASeq. EPHA3 is a receptor tyrosine kinase that is frequently mutated in lung cancer. Tumor-suppressive effects of wild-type EPHA3 can be overridden by dominant negative EPHA3 somatic mutations [<xref rid="B20" ref-type="bibr">28</xref>]. This mechanism is unlikely to play a role in this sarcoma as the detected mutation is located far N-terminally on the extracellular Ephrin binding domain not on the intracellular kinase domain.</p><p>FAF1 has been described to act as a tumor suppressor gene [<xref rid="B21" ref-type="bibr">29</xref>]. Its depletion due to chromosome breakage can affect prognosis in glioblastoma patients [<xref rid="B22" ref-type="bibr">30</xref>, <xref rid="B23" ref-type="bibr">31</xref>]. Single nucleotide polymorphisms in FAF1 are associated with a risk for gastric cancer [<xref rid="B24" ref-type="bibr">32</xref>]. While numerous FAF1 mutations are associated with various cancers, none of these genetic changes in the TCGA database affects the amino acid position 181 (<xref ref-type="table" rid="tab4">Table 4</xref>).</p><p>The major upregulations identified in this tumor comprise muscle-specific gene products (transcription factors: CAAC binding; proteomics: transgelin, transgelin-2; RNA: anoctamin-4; and immunohistochemistry: smooth muscle actin) and calcium-regulating molecules (proteomics: calumenin, S100-A11, reticulocalbin-3, and 78&#x02009;kD glucose-regulated protein). The muscle-specific gene products confirm this recurrent sarcoma as a leiomyosarcoma (the first tumor, distal to the site of the recurring one, had been diagnosed as an osteosarcoma). Calcium is one of the major second messengers in smooth muscle cells. Its uptake is regulated by potential-sensitive ion channels in the cell membrane and by the activities of various receptors. Calcium is stored in the sarcoplasmic reticulum, from where it can be released to facilitate actin-myosin interaction and tension generation. Phosphorylation of the myosin light chain by a calmodulin-regulated enzyme is important for contraction. The upregulation of gene products associated with migration and invasion (osteopontin, MMP1, vimentin, filamin-A, and <italic>&#x003b2;</italic>-actin) and gene products for extracellular matrix molecules and their modulators (fibronectin, collagen, ITGBL1, and MXRA5) reflects the invasive nature of this cancer.</p><p>The recurrence of a sarcoma after 14 years has two probable explanations, either it is due to a cancer predisposition syndrome based on a germ-line mutation (the age of the patient weakens this hypothesis) or the second tumor is a metastatic colony of the first that was reactivated after dormancy. The location of the sarcoma in the same extremity and proximal to a preceding mesenchymal cancer (and therefore in its natural path of dissemination) implied the probability that this was a relapse in a metastatic site. The different histologic assessment as osteosarcoma in the first occurrence and leiomyosarcoma as the second cancer does not necessarily negate that. Mixed histology [<xref rid="B25" ref-type="bibr">33</xref>, <xref rid="B26" ref-type="bibr">34</xref>] and transdifferentiation [<xref rid="B27" ref-type="bibr">35</xref>&#x02013;<xref rid="B29" ref-type="bibr">37</xref>] have been described for sarcomatous tumors. Of note, however, in this scenario osteosarcoma seems to more commonly follow leiomyosarcoma than precede it. Material from the first cancer of this patient was not accessible to us. It is very plausible that this could have been a mineralized leiomyosarcoma. In those tumors, the differential diagnosis from osteosarcoma can be difficult [<xref rid="B30" ref-type="bibr">38</xref>]. The extracompartmental location of the first tumor supports this interpretation.</p><p>On the molecular pathology level, sarcomas fall into two groups, comprising tumors with simple karyotypes (with pathogenetic translocations or specific genetic mutations) and tumors with very complex karyotypes (overt chromosome and genomic instability with numerous gains and losses) [<xref rid="B31" ref-type="bibr">39</xref>]. Some molecular alterations that lead to carcinogenesis can be defined in absolute terms. They include gain-of-function mutations or chromosome translocations that transform protooncogenes to oncogenes. However, other changes are relative to the normal tissue of origin, such as pathway overactivity or overexpression on the protein or RNA levels. We have combined the analysis of absolute changes (DNA exome sequence, RNA sequence) with the analysis of relative changes using skeletal muscle and bone as reference organs (protein-DNA array, 2D gel electrophoresis, and RNA expression levels). This choice was determined in part by tissue availability after surgery and was intended to aid in the distinction of osteosarcoma from myosarcoma. While a more accurate reference point for a leiomyosarcoma would have been smooth muscle, we believe that the comparison to striated muscle is sufficient to allow the assessment of tumor specific changes. We have measured RNA, DNA, and protein with various assays. Similar assessments in the future should also include chromosome analysis for possible translocations.</p><p>In the first-line defense against cancer, the gradual replacement of conventional chemotherapy with molecularly targeted agents has opened the possibility to tailor drug treatments to particular tumors. This transition necessitates the characterization of the molecular lesions that are causative for the transformation of healthy cells into cancerous cells, because drugs need to be matched with the underlying carcinogenic defect to be effective. An additional caveat, caused by unique genetic changes in the primary tumor, can affect drug transport and metabolism and needs to be taken into consideration. In this case, the RNA levels for genes that regulate transport and metabolism were extensively skewed in the tumor tissue as compared to muscle and bone (see <xref ref-type="table" rid="tab3">Table 3</xref>), implying potential challenges to chemotherapy. An advanced molecular treatment strategy for cancer will rely on the molecular definition of drug target, drug transport, and drug metabolism pharmacogenetics in the primary tumor. Consecutive to cancer dissemination, it will also require adjustments to account for the genetic changes in the metastases.</p><p>The cost of health care has been under increasing scrutiny. The treatment of cancer patients is expensive, in particular when hospitalization is required, and further in cases of end-of-life care. Avoidable expenditures are generated by suboptimal treatment decisions that result in low efficacy or high toxicity of anticancer regimens. Molecular medicine has the potential to preempt those problems and reduce wasteful spending. Yet, it requires the upfront cost of molecular cancer examination. The analysis performed in this study required about $11,000.- in nonsalary expenses to perform. While it has not identified a drug target, it has specified possible confines for drug treatment. The costs for molecular analysis need to be weighed against the societal cost derived from lost productivity in the workforce, disrupted lives of families, and premature deaths. While currently limited drug options constitute the major constraint to the approach taken here, the foreseeable future will bring an increasing spectrum of molecularly targeted drugs along with faster and cheaper technologies for the molecular assessment of cancers. They will facilitate the clinical translation of our approach.</p></sec></body><back><ack><title>Acknowledgments</title><p>This research was supported by DOD Grant PR094070 under University of Cincinnati IRB protocol 04-01-29-01. The author is grateful to Dr. Rhett Kovall for helping with the structural analysis of FAF1.</p></ack><sec><title>Consent</title><p>The patient provided informed consent.</p></sec><sec sec-type="conflict"><title>Conflict of Interests</title><p>The author declares that there is no conflict of interests regarding the publication of this paper.</p></sec><ref-list><ref id="B1"><label>1</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Weber</surname><given-names>G. F.</given-names></name></person-group><source><italic>Molecular Mechanisms of Cancer</italic></source><year>2007</year><publisher-loc>Dordrecht, The Netherlands</publisher-loc><publisher-name>Springer</publisher-name></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanerkin</surname><given-names>N. G.</given-names></name></person-group><article-title>Primary leiomyosarcoma of the bone and its comparison with fibrosarcoma</article-title><source><italic>Cancer</italic></source><year>1979</year><volume>44</volume><issue>4</issue><fpage>1375</fpage><lpage>1387</lpage><pub-id pub-id-type="doi">10.1002/1097-0142(197910)44:460;1375::aid-cncr282044043162;3.0.co;2-0</pub-id><pub-id pub-id-type="other">2-s2.0-0018627764</pub-id><pub-id pub-id-type="pmid">91423</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="other"><person-group person-group-type="author"><name><surname>Weaver</surname><given-names>J. M.</given-names></name><name><surname>Abraham</surname><given-names>J. A.</given-names></name></person-group><article-title>Leiomyosarcoma of the Bone and Soft Tissue: A Review</article-title><comment><ext-link ext-link-type="uri" xlink:href="http://sarcomahelp.org/learning_center/leiomyosarcoma.html">http://sarcomahelp.org/learning_center/leiomyosarcoma.html</ext-link></comment></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Depristo</surname><given-names>M. A.</given-names></name><name><surname>Banks</surname><given-names>E.</given-names></name><name><surname>Poplin</surname><given-names>R.</given-names></name><etal/></person-group><article-title>A framework for variation discovery and genotyping using next-generation DNA sequencing data</article-title><source><italic>Nature Genetics</italic></source><year>2011</year><volume>43</volume><issue>5</issue><fpage>491</fpage><lpage>501</lpage><pub-id pub-id-type="doi">10.1038/ng.806</pub-id><pub-id pub-id-type="other">2-s2.0-79955483667</pub-id><pub-id pub-id-type="pmid">21478889</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>H.</given-names></name><name><surname>Durbin</surname><given-names>R.</given-names></name></person-group><article-title>Fast and accurate short read alignment with Burrows-Wheeler transform</article-title><source><italic>Bioinformatics</italic></source><year>2009</year><volume>25</volume><issue>14</issue><fpage>1754</fpage><lpage>1760</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btp324</pub-id><pub-id pub-id-type="other">2-s2.0-67649884743</pub-id><pub-id pub-id-type="pmid">19451168</pub-id></element-citation></ref><ref id="B11"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Menges</surname><given-names>C. W.</given-names></name><name><surname>Altomare</surname><given-names>D. A.</given-names></name><name><surname>Testa</surname><given-names>J. R.</given-names></name></person-group><article-title>FAS-associated factor 1 (FAF1): diverse functions and implications for oncogenesis</article-title><source><italic>Cell Cycle</italic></source><year>2009</year><volume>8</volume><issue>16</issue><fpage>2528</fpage><lpage>2534</lpage><pub-id pub-id-type="doi">10.4161/cc.8.16.9280</pub-id><pub-id pub-id-type="other">2-s2.0-69249211227</pub-id><pub-id pub-id-type="pmid">19597341</pub-id></element-citation></ref><ref id="B38"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>M.</given-names></name><name><surname>Lee</surname><given-names>J. H.</given-names></name><name><surname>Lee</surname><given-names>S. Y.</given-names></name><name><surname>Kim</surname><given-names>E.</given-names></name><name><surname>Chung</surname><given-names>J.</given-names></name></person-group><article-title>Caspar, a suppressor of antibacterial immunity in <italic>Drosophila</italic></article-title><source><italic>Proceedings of the National Academy of Sciences of the United States of America</italic></source><year>2006</year><volume>103</volume><issue>44</issue><fpage>16358</fpage><lpage>16363</lpage><pub-id pub-id-type="doi">10.1073/pnas.0603238103</pub-id><pub-id pub-id-type="other">2-s2.0-33750842525</pub-id><pub-id pub-id-type="pmid">17050695</pub-id></element-citation></ref><ref id="B39"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>J.</given-names></name><name><surname>Joon</surname><given-names>K. P.</given-names></name><name><surname>Lee</surname><given-names>J.-J.</given-names></name><etal/></person-group><article-title>Structure and interaction of ubiquitin-associated domain of human Fas-associated factor 1</article-title><source><italic>Protein Science</italic></source><year>2009</year><volume>18</volume><issue>11</issue><fpage>2265</fpage><lpage>2276</lpage><pub-id pub-id-type="doi">10.1002/pro.237</pub-id><pub-id pub-id-type="other">2-s2.0-70350511436</pub-id><pub-id pub-id-type="pmid">19722279</pub-id></element-citation></ref><ref id="B6"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O'Farrell</surname><given-names>P. H.</given-names></name></person-group><article-title>High resolution two dimensional electrophoresis of proteins</article-title><source><italic>Journal of Biological Chemistry</italic></source><year>1975</year><volume>250</volume><issue>10</issue><fpage>4007</fpage><lpage>4021</lpage><pub-id pub-id-type="other">2-s2.0-0016711037</pub-id><pub-id pub-id-type="pmid">236308</pub-id></element-citation></ref><ref id="B7"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burgess-Cassler</surname><given-names>A.</given-names></name><name><surname>Johansen</surname><given-names>J. J.</given-names></name><name><surname>Santek</surname><given-names>D. A.</given-names></name><name><surname>Ide</surname><given-names>J. R.</given-names></name><name><surname>Kendrick</surname><given-names>N. C.</given-names></name></person-group><article-title>Computerized quantitative analysis of Coomassie-Blue-stained serum proteins separated by two-dimensional electrophoresis</article-title><source><italic>Clinical Chemistry</italic></source><year>1989</year><volume>35</volume><issue>12</issue><fpage>2297</fpage><lpage>2304</lpage><pub-id pub-id-type="other">2-s2.0-0024806722</pub-id><pub-id pub-id-type="pmid">2480196</pub-id></element-citation></ref><ref id="B8"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oakley</surname><given-names>B. R.</given-names></name><name><surname>Kirsch</surname><given-names>D. R.</given-names></name><name><surname>Morris</surname><given-names>N. R.</given-names></name></person-group><article-title>A simplified ultrasensitive silver stain for detecting proteins in polyacrylamide gels</article-title><source><italic>Analytical Biochemistry</italic></source><year>1980</year><volume>105</volume><issue>2</issue><fpage>361</fpage><lpage>363</lpage><pub-id pub-id-type="doi">10.1016/0003-2697(80)90470-4</pub-id><pub-id pub-id-type="other">2-s2.0-0019042327</pub-id><pub-id pub-id-type="pmid">6161559</pub-id></element-citation></ref><ref id="B9"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chu</surname><given-names>K.</given-names></name><name><surname>Niu</surname><given-names>X.</given-names></name><name><surname>Williams</surname><given-names>L. T.</given-names></name></person-group><article-title>A Fas-associated protein factor, FAF1, potentiates Fas-mediated apoptosis</article-title><source><italic>Proceedings of the National Academy of Sciences of the United States of America</italic></source><year>1995</year><volume>92</volume><issue>25</issue><fpage>11894</fpage><lpage>11898</lpage><pub-id pub-id-type="doi">10.1073/pnas.92.25.11894</pub-id><pub-id pub-id-type="other">2-s2.0-0029616220</pub-id><pub-id pub-id-type="pmid">8524870</pub-id></element-citation></ref><ref id="B10"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rikhof</surname><given-names>B.</given-names></name><name><surname>de Jong</surname><given-names>S.</given-names></name><name><surname>Suurmeijer</surname><given-names>A. J. H.</given-names></name><name><surname>Meijer</surname><given-names>C.</given-names></name><name><surname>van der Graaf</surname><given-names>W. T. A.</given-names></name></person-group><article-title>The insulin-like growth factor system and sarcomas</article-title><source><italic>The Journal of Pathology</italic></source><year>2009</year><volume>217</volume><issue>4</issue><fpage>469</fpage><lpage>482</lpage><pub-id pub-id-type="doi">10.1002/path.2499</pub-id><pub-id pub-id-type="other">2-s2.0-62849105383</pub-id><pub-id pub-id-type="pmid">19148905</pub-id></element-citation></ref><ref id="B32"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Girling</surname><given-names>R.</given-names></name><name><surname>Partridge</surname><given-names>J. F.</given-names></name><name><surname>Bandara</surname><given-names>L. R.</given-names></name><etal/></person-group><article-title>A new component of the transcription factor DRTF1/E2F</article-title><source><italic>Nature</italic></source><year>1993</year><volume>362</volume><issue>6415</issue><fpage>83</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.1038/362083a0</pub-id><pub-id pub-id-type="other">2-s2.0-0027512510</pub-id><pub-id pub-id-type="pmid">8446173</pub-id></element-citation></ref><ref id="B33"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mercurio</surname><given-names>F.</given-names></name><name><surname>Karin</surname><given-names>M.</given-names></name></person-group><article-title>Transcription factors AP-3 and AP-2 interact with the SV40 enhancer in a mutually exclusive manner</article-title><source><italic>EMBO Journal</italic></source><year>1989</year><volume>8</volume><issue>5</issue><fpage>1455</fpage><lpage>1460</lpage><pub-id pub-id-type="other">2-s2.0-0024384881</pub-id><pub-id pub-id-type="pmid">2548845</pub-id></element-citation></ref><ref id="B34"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bassel-Duby</surname><given-names>R.</given-names></name><name><surname>Hernandez</surname><given-names>M. D.</given-names></name><name><surname>Gonzalez</surname><given-names>M. A.</given-names></name><name><surname>Krueger</surname><given-names>J. K.</given-names></name><name><surname>Williams</surname><given-names>R. S.</given-names></name></person-group><article-title>A 40-kilodalton protein binds specifically to an upstream sequence element essential for muscle-specific transcription of the human myoglobin promoter</article-title><source><italic>Molecular and Cellular Biology</italic></source><year>1992</year><volume>12</volume><issue>11</issue><fpage>5024</fpage><lpage>5032</lpage><pub-id pub-id-type="other">2-s2.0-0026661836</pub-id><pub-id pub-id-type="pmid">1406677</pub-id></element-citation></ref><ref id="B35"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamada</surname><given-names>K.</given-names></name><name><surname>Tanaka</surname><given-names>T.</given-names></name><name><surname>Noguchi</surname><given-names>T.</given-names></name></person-group><article-title>Characterization and purification of carbohydrate response element-binding protein of the rat L-type pyruvate kinase gene promoter</article-title><source><italic>Biochemical and Biophysical Research Communications</italic></source><year>1999</year><volume>257</volume><issue>1</issue><fpage>44</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.1006/bbrc.1999.0410</pub-id><pub-id pub-id-type="other">2-s2.0-0033515845</pub-id><pub-id pub-id-type="pmid">10092507</pub-id></element-citation></ref><ref id="B36"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guan</surname><given-names>G.</given-names></name><name><surname>Jiang</surname><given-names>G.</given-names></name><name><surname>Koch</surname><given-names>R. L.</given-names></name><name><surname>Shechter</surname><given-names>I.</given-names></name></person-group><article-title>Molecular cloning and functional analysis of the promoter of the human squalene synthase gene</article-title><source><italic>The Journal of Biological Chemistry</italic></source><year>1995</year><volume>270</volume><issue>37</issue><fpage>21958</fpage><lpage>21965</lpage><pub-id pub-id-type="doi">10.1074/jbc.270.37.21958</pub-id><pub-id pub-id-type="other">2-s2.0-0029100908</pub-id><pub-id pub-id-type="pmid">7665618</pub-id></element-citation></ref><ref id="B37"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jordan</surname><given-names>T.</given-names></name><name><surname>Hanson</surname><given-names>I.</given-names></name><name><surname>Zaletayev</surname><given-names>D.</given-names></name><etal/></person-group><article-title>The human PAX6 gene is mutated in two patients with aniridia</article-title><source><italic>Nature Genetics</italic></source><year>1992</year><volume>1</volume><issue>5</issue><fpage>328</fpage><lpage>332</lpage><pub-id pub-id-type="doi">10.1038/ng0892-328</pub-id><pub-id pub-id-type="other">2-s2.0-0026907123</pub-id><pub-id pub-id-type="pmid">1302030</pub-id></element-citation></ref><ref id="B12"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>F.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Gong</surname><given-names>K.</given-names></name><etal/></person-group><article-title>LEF-1 activates the transcription of E2F1</article-title><source><italic>Biochemical and Biophysical Research Communications</italic></source><year>2008</year><volume>365</volume><issue>1</issue><fpage>149</fpage><lpage>153</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2007.10.138</pub-id><pub-id pub-id-type="other">2-s2.0-36049017658</pub-id><pub-id pub-id-type="pmid">17980157</pub-id></element-citation></ref><ref id="B13"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Zhou</surname><given-names>F.</given-names></name><name><surname>van Laar</surname><given-names>T.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>van Dam</surname><given-names>H.</given-names></name><name><surname>Ten Dijke</surname><given-names>P.</given-names></name></person-group><article-title>Fas-associated factor 1 antagonizes Wnt signaling by promoting <italic>&#x003b2;</italic>-catenin degradation</article-title><source><italic>Molecular Biology of the Cell</italic></source><year>2011</year><volume>22</volume><issue>9</issue><fpage>1617</fpage><lpage>1624</lpage><pub-id pub-id-type="other">2-s2.0-79955492739</pub-id><pub-id pub-id-type="doi">10.1091/mbc.e10-12-0985</pub-id><pub-id pub-id-type="pmid">21411632</pub-id></element-citation></ref><ref id="B14"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Noubissi</surname><given-names>F. K.</given-names></name><name><surname>Elcheva</surname><given-names>I.</given-names></name><name><surname>Bhatia</surname><given-names>N.</given-names></name><etal/></person-group><article-title>CRD-BP mediates stabilization of <italic>
&#x003b2;TrCP1</italic> and <italic>c-myc</italic> mRNA in response to <italic>&#x003b2;</italic>-catenin signalling</article-title><source><italic>Nature</italic></source><year>2006</year><volume>441</volume><issue>7095</issue><fpage>898</fpage><lpage>901</lpage><pub-id pub-id-type="other">2-s2.0-33745225167</pub-id><pub-id pub-id-type="doi">10.1038/nature04839</pub-id><pub-id pub-id-type="pmid">16778892</pub-id></element-citation></ref><ref id="B15"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elcheva</surname><given-names>I.</given-names></name><name><surname>Tarapore</surname><given-names>R. S.</given-names></name><name><surname>Bhatia</surname><given-names>N.</given-names></name><name><surname>Spiegelman</surname><given-names>V. S.</given-names></name></person-group><article-title>Overexpression of mRNA-binding protein CRD-BP in malignant melanomas</article-title><source><italic>Oncogene</italic></source><year>2008</year><volume>27</volume><issue>37</issue><fpage>5069</fpage><lpage>5074</lpage><pub-id pub-id-type="other">2-s2.0-50649102813</pub-id><pub-id pub-id-type="doi">10.1038/onc.2008.141</pub-id><pub-id pub-id-type="pmid">18454174</pub-id></element-citation></ref><ref id="B16"><label>24</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>C. H.</given-names></name><name><surname>Ji</surname><given-names>T.</given-names></name><name><surname>Chen</surname><given-names>C. F.</given-names></name><name><surname>Hoang</surname><given-names>B. H.</given-names></name></person-group><article-title>Wnt signaling in osteosarcoma</article-title><source><italic>Current Advances in Osteosarcoma</italic></source><year>2014</year><volume>804</volume><publisher-name>Springer</publisher-name><fpage>33</fpage><lpage>45</lpage><series>Advances in Experimental Medicine and Biology</series><pub-id pub-id-type="doi">10.1007/978-3-319-04843-7_2</pub-id></element-citation></ref><ref id="B17"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>S. M.</given-names></name><name><surname>Myoung</surname><given-names>H.</given-names></name><name><surname>Choung</surname><given-names>P. H.</given-names></name><name><surname>Kim</surname><given-names>M. J.</given-names></name><name><surname>Lee</surname><given-names>S. K.</given-names></name><name><surname>Lee</surname><given-names>J. H.</given-names></name></person-group><article-title>Metastatic leiomyosarcoma in the oral cavity: case report with protein expression profiles</article-title><source><italic>Journal of Cranio-Maxillofacial Surgery</italic></source><year>2009</year><volume>37</volume><issue>8</issue><fpage>454</fpage><lpage>460</lpage><pub-id pub-id-type="doi">10.1016/j.jcms.2009.06.010</pub-id><pub-id pub-id-type="other">2-s2.0-70350575170</pub-id><pub-id pub-id-type="pmid">19664933</pub-id></element-citation></ref><ref id="B18"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hrzenjak</surname><given-names>A.</given-names></name><name><surname>Dieber-Rotheneder</surname><given-names>M.</given-names></name><name><surname>Moinfar</surname><given-names>F.</given-names></name><name><surname>Petru</surname><given-names>E.</given-names></name><name><surname>Zatloukal</surname><given-names>K.</given-names></name></person-group><article-title>Molecular mechanisms of endometrial stromal sarcoma and undifferentiated endometrial sarcoma as premises for new therapeutic strategies</article-title><source><italic>Cancer Letters</italic></source><year>2014</year><volume>354</volume><issue>1</issue><fpage>21</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1016/j.canlet.2014.08.013</pub-id><pub-id pub-id-type="pmid">25128649</pub-id></element-citation></ref><ref id="B19"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mohan</surname><given-names>H. M.</given-names></name><name><surname>Aherne</surname><given-names>C. M.</given-names></name><name><surname>Rogers</surname><given-names>A. C.</given-names></name><name><surname>Baird</surname><given-names>A. W.</given-names></name><name><surname>Winter</surname><given-names>D. C.</given-names></name><name><surname>Murphy</surname><given-names>E. P.</given-names></name></person-group><article-title>Molecular pathways: the role of NR4A orphan nuclear receptors in cancer</article-title><source><italic>Clinical Cancer Research</italic></source><year>2012</year><volume>18</volume><issue>12</issue><fpage>3223</fpage><lpage>3228</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.ccr-11-2953</pub-id><pub-id pub-id-type="other">2-s2.0-84862545879</pub-id><pub-id pub-id-type="pmid">22566377</pub-id></element-citation></ref><ref id="B20"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhuang</surname><given-names>G.</given-names></name><name><surname>Song</surname><given-names>W.</given-names></name><name><surname>Amato</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Effects of cancer-associated EPHA3 mutations on lung cancer</article-title><source><italic>Journal of the National Cancer Institute</italic></source><year>2012</year><volume>104</volume><issue>15</issue><fpage>1182</fpage><lpage>1197</lpage><pub-id pub-id-type="doi">10.1093/jnci/djs297</pub-id><pub-id pub-id-type="other">2-s2.0-84864951407</pub-id><pub-id pub-id-type="pmid">22829656</pub-id></element-citation></ref><ref id="B21"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>J.-J.</given-names></name><name><surname>Kim</surname><given-names>Y. M.</given-names></name><name><surname>Jeong</surname><given-names>J.</given-names></name><name><surname>Bae</surname><given-names>D. S.</given-names></name><name><surname>Lee</surname><given-names>K.-J.</given-names></name></person-group><article-title>Ubiquitin-associated (UBA) domain in human fas associated factor 1 inhibits tumor formation by promoting Hsp70 degradation</article-title><source><italic>PLoS ONE</italic></source><year>2012</year><volume>7</volume><issue>8</issue><pub-id pub-id-type="publisher-id">e40361</pub-id><pub-id pub-id-type="doi">10.1371/journal.pone.0040361</pub-id><pub-id pub-id-type="other">2-s2.0-84864419019</pub-id></element-citation></ref><ref id="B22"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>S.</given-names></name><name><surname>Fu</surname><given-names>J.</given-names></name><name><surname>Vegesna</surname><given-names>R.</given-names></name><etal/></person-group><article-title>A survey of intragenic breakpoints in glioblastoma identifies a distinct subset associated with poor survival</article-title><source><italic>Genes and Development</italic></source><year>2013</year><volume>27</volume><issue>13</issue><fpage>1462</fpage><lpage>1472</lpage><pub-id pub-id-type="other">2-s2.0-84879764400</pub-id><pub-id pub-id-type="doi">10.1101/gad.213686.113</pub-id><pub-id pub-id-type="pmid">23796897</pub-id></element-citation></ref><ref id="B23"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carvalho</surname><given-names>D.</given-names></name><name><surname>Mackay</surname><given-names>A.</given-names></name><name><surname>Bjerke</surname><given-names>L.</given-names></name><etal/></person-group><article-title>The prognostic role of intragenic copy number breakpoints and identification of novel fusion genes in paediatric high grade glioma</article-title><source><italic>Acta Neuropathologica Communications</italic></source><year>2014</year><volume>2</volume><issue>1</issue><fpage>p. 23</fpage><pub-id pub-id-type="doi">10.1186/2051-5960-2-23</pub-id></element-citation></ref><ref id="B24"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hyland</surname><given-names>P. L.</given-names></name><name><surname>Lin</surname><given-names>S.-W.</given-names></name><name><surname>Hu</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Genetic variants in fas signaling pathway genes and risk of gastric cancer</article-title><source><italic>International Journal of Cancer</italic></source><year>2014</year><volume>134</volume><issue>4</issue><fpage>822</fpage><lpage>831</lpage><pub-id pub-id-type="doi">10.1002/ijc.28415</pub-id><pub-id pub-id-type="other">2-s2.0-84890130014</pub-id></element-citation></ref><ref id="B25"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y.-F.</given-names></name><name><surname>Yu</surname><given-names>C.-P.</given-names></name><name><surname>Wu</surname><given-names>S.-T.</given-names></name><name><surname>Dai</surname><given-names>M.-S.</given-names></name><name><surname>Lee</surname><given-names>H.-S.</given-names></name></person-group><article-title>Malignant mesenchymal tumor with leiomyosarcoma, rhabdomyosarcoma, chondrosarcoma, and osteosarcoma differentiation: case report and literature review</article-title><source><italic>Diagnostic Pathology</italic></source><year>2011</year><volume>6, article 35</volume><pub-id pub-id-type="doi">10.1186/1746-1596-6-35</pub-id><pub-id pub-id-type="other">2-s2.0-79955112857</pub-id></element-citation></ref><ref id="B26"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kefeli</surname><given-names>M.</given-names></name><name><surname>Baris</surname><given-names>S.</given-names></name><name><surname>Aydin</surname><given-names>O.</given-names></name><name><surname>Yildiz</surname><given-names>L.</given-names></name><name><surname>Yamak</surname><given-names>S.</given-names></name><name><surname>Kandemir</surname><given-names>B.</given-names></name></person-group><article-title>An unusual case of an osteosarcoma arising in a leiomyoma of the uterus</article-title><source><italic>Annals of Saudi Medicine</italic></source><year>2012</year><volume>32</volume><issue>5</issue><fpage>544</fpage><lpage>546</lpage><pub-id pub-id-type="other">2-s2.0-84868630917</pub-id><pub-id pub-id-type="pmid">22634486</pub-id></element-citation></ref><ref id="B27"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feeley</surname><given-names>C.</given-names></name><name><surname>Gallagher</surname><given-names>P.</given-names></name><name><surname>Lang</surname><given-names>D.</given-names></name></person-group><article-title>Osteosarcoma arising in a metastatic leiomyosarcoma</article-title><source><italic>Histopathology</italic></source><year>2005</year><volume>46</volume><issue>1</issue><fpage>111</fpage><lpage>113</lpage><pub-id pub-id-type="other">2-s2.0-13244291708</pub-id><pub-id pub-id-type="doi">10.1111/j.1365-2559.2005.01983.x</pub-id><pub-id pub-id-type="pmid">15656897</pub-id></element-citation></ref><ref id="B28"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grabellus</surname><given-names>F.</given-names></name><name><surname>Sheu</surname><given-names>S.-Y.</given-names></name><name><surname>Schmidt</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Recurrent high-grade leiomyosarcoma with heterologous osteosarcomatous differentiation</article-title><source><italic>Virchows Archiv</italic></source><year>2006</year><volume>448</volume><issue>1</issue><fpage>85</fpage><lpage>89</lpage><pub-id pub-id-type="doi">10.1007/s00428-005-0094-0</pub-id><pub-id pub-id-type="other">2-s2.0-31744446051</pub-id><pub-id pub-id-type="pmid">16228225</pub-id></element-citation></ref><ref id="B29"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anh Tran</surname><given-names>T.</given-names></name><name><surname>Holloway</surname><given-names>R. W.</given-names></name></person-group><article-title>Metastatic leiomyosarcoma of the uterus with heterologous differentiation to malignant mesenchymoma</article-title><source><italic>International Journal of Gynecological Pathology</italic></source><year>2012</year><volume>31</volume><issue>5</issue><fpage>453</fpage><lpage>457</lpage><pub-id pub-id-type="doi">10.1097/PGP.0b013e318246977d</pub-id><pub-id pub-id-type="other">2-s2.0-84864838331</pub-id><pub-id pub-id-type="pmid">22833086</pub-id></element-citation></ref><ref id="B30"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bush</surname><given-names>C. H.</given-names></name><name><surname>Reith</surname><given-names>J. D.</given-names></name><name><surname>Spanier</surname><given-names>S. S.</given-names></name></person-group><article-title>Mineralization in musculoskeletal leiomyosarcoma: radiologic-pathologic correlation</article-title><source><italic>The American Journal of Roentgenology</italic></source><year>2003</year><volume>180</volume><issue>1</issue><fpage>109</fpage><lpage>113</lpage><pub-id pub-id-type="doi">10.2214/ajr.180.1.1800109</pub-id><pub-id pub-id-type="other">2-s2.0-0037208666</pub-id></element-citation></ref><ref id="B31"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Osuna</surname><given-names>D.</given-names></name><name><surname>de &#x000c1;lava</surname><given-names>E.</given-names></name></person-group><article-title>Molecular pathology of sarcomas</article-title><source><italic>Reviews on Recent Clinical Trials</italic></source><year>2009</year><volume>4</volume><issue>1</issue><fpage>12</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.2174/157488709787047585</pub-id><pub-id pub-id-type="other">2-s2.0-62449159552</pub-id><pub-id pub-id-type="pmid">19149759</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="fig1" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Osteosarcoma. (a) Whole body scan shows abnormally intense uptake of the radionuclide (Tc) within the middiaphysis of the right femur. No increased radionuclide uptake is seen anywhere else in the bony skeleton. (b) MRI scan displays an extensively abnormal signal in the diaphysis of the right femur. It is surrounded by soft tissue involvement. (c) Bone lesion displayed postoperatively.</p></caption><graphic xlink:href="SARCOMA2015-839182.001"/></fig><fig id="fig2" orientation="portrait" position="float"><label>Figure 2</label><caption><p>FAF1 structure. (a) A schematic of functional domains in FAF1 with annotations (adapted from [<xref rid="B11" ref-type="bibr">6</xref>&#x02013;<xref rid="B39" ref-type="bibr">8</xref>]). There are two ubiquitin-like domains flanking the S181 site. The PDB structure 2DZM identifies the N-terminal one, while the C-terminal prediction is by sequence similarity. Whereas the mutation S181G is not expected to disrupt the protein structure per se, this amino acid has a high score as a possible phosphorylation site for a number of kinases involved in DNA damage repair. (b) Secondary structure prediction of FAF1. The residues around S181 appear unstructured.</p></caption><graphic xlink:href="SARCOMA2015-839182.002"/></fig><fig id="fig3" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Transcription factor activation. Nuclear extracts from tumor, muscle, and bone were tested for DNA binding activity on a protein-DNA array. (a) Transcription factor binding that was high in all 3 tissues and is therefore considered constitutively active is circled in yellow (left to right, top to bottom: AhR/Amt, GATA1, GATA2, GATA1/2, HIF1, and HOXD8/9/10). Transcription factors that show high binding in the cancer, but not in muscle or bone, are circled in red (left to right, top to bottom: E2F1, AP3, LIII-BP, PAX6, ADD-1, and CCAC). (b) The functions of transcription factors that display high DNA binding in the cancer, but not in muscle or bone, are described.</p></caption><graphic xlink:href="SARCOMA2015-839182.003"/></fig><fig id="fig4" orientation="portrait" position="float"><label>Figure 4</label><caption><p>Protein overexpression. (a) 2D protein gel electrophoresis of lysates from muscle (upper left), tumor (upper right), and bone (bottom) in RIPA buffer. Red circles indicate the spots that were identified as overexpressed and were further analyzed by mass spectrometry. (b) Proteins identified in 2D gel electrophoresis as overexpressed in the tumor in comparison to muscle and bone were analyzed for their identity by mass spectrometry. The left column indicates the spot number corresponding to the 2D gel. The next column contains the protein name, followed by the accession number and a description of the protein function. The protein functions are grouped into structural, calcium homeostasis, and various others. (c) Western blot. 10&#x02009;<italic>&#x003bc;</italic>g lysates of tumor, muscle, and bone in RIPA buffer were loaded per lane and electrophoresed on 10% SDS-polyacrylamide minigels with reducing, denaturing sample buffer. After transfer to PVDF membranes, they were probed for markers of cancer progression, including osteopontin, CD44, STAT3, and phospho-STAT3. Antitubulin served as a loading control. (d) RNA levels corresponding to the proteins found to be affected in the sarcoma. With four exceptions in the tumor-bone comparison (gray font), upregulated proteins are associated with increased RNA levels. STAT3 is not increased on the protein or RNA level. The reduced level of RB1 expression is consistent with the elevated DNA binding activity of E2F1.</p></caption><graphic xlink:href="SARCOMA2015-839182.004"/></fig><fig id="fig5" orientation="portrait" position="float"><label>Figure 5</label><caption><p>Possible transforming pathway. The point mutation in FAF1 is believed to cause a loss of function (crossed out in red). This may lead to an overactivity of the WNT signaling pathway. Consistently, E2F1 (activated by LEF1) and<italic> igf2bp1</italic> (a transcriptional target of the WNT pathway) have been identified to be upregulated in the molecular analysis. In contrast to the negative regulator FAF1, IGF2BP1 is a positive regulator of NF-<italic>&#x003ba;</italic>B activity. The overactivity of the NF-<italic>&#x003ba;</italic>B pathway and the reduced efficacy of FAS signaling can be transforming.</p></caption><graphic xlink:href="SARCOMA2015-839182.005"/></fig><table-wrap id="tab1" orientation="portrait" position="float"><label>Table 1</label><caption><p>DNA exome SNPs. The DNA exomes for tumor, muscle, and bone were sequenced. The results were filtered in the following order: (1) different genotype in tumor from muscle and bone, with muscle and bone being identical to each other, (2) delete mutations with low confidence (value of 20 or lower) in all 3 tissues, (3) delete unidentified genes, (4) delete mutations that are homozygous reference in the tumor, (5) delete mutations that have a MAF in dbSNP &#x0003e;10%, (6) delete low impact and modifier mutations. The gene names are part of the key in the left column. In this column, results on bold&#x02009;font represent SNPs that were confirmed on the RNA level by RNASeq. The data files have been submitted to the NCBI short read archive (SRA) under the accession number SRP052797 (biosamples SAMN03316820, SAMN03316821, SAMN03316822).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Key</th><th align="center" rowspan="1" colspan="1">Chromosome</th><th align="center" rowspan="1" colspan="1">Position</th><th align="center" rowspan="1" colspan="1">Reference</th><th align="center" rowspan="1" colspan="1">Alternate</th><th align="center" rowspan="1" colspan="1">dbSNP ID</th><th align="center" rowspan="1" colspan="1">dbSNP MAF</th><th align="center" rowspan="1" colspan="1">ESP MAF (All)</th><th align="center" rowspan="1" colspan="1">ESP MAF (EA)</th><th align="center" rowspan="1" colspan="1">ESP MAF (AA)</th><th align="center" rowspan="1" colspan="1">Consensus impact</th><th align="center" rowspan="1" colspan="1">Bone/muscle genotype</th><th align="center" rowspan="1" colspan="1">Bone overall depth</th><th align="center" rowspan="1" colspan="1">Bone allele depths</th><th align="center" rowspan="1" colspan="1">Bone quality</th><th align="center" rowspan="1" colspan="1">Muscle overall depth</th><th align="center" rowspan="1" colspan="1">Muscle allele depths</th><th align="center" rowspan="1" colspan="1">Muscle quality</th><th align="center" rowspan="1" colspan="1">Tumor genotype</th><th align="center" rowspan="1" colspan="1">Tumor overall depth</th><th align="center" rowspan="1" colspan="1">Tumor allele depths</th><th align="center" rowspan="1" colspan="1">Tumor quality</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">
<bold>17_7479998_T_EIF4A1</bold>
</td><td align="center" rowspan="1" colspan="1">17</td><td align="center" rowspan="1" colspan="1">7479998</td><td align="center" rowspan="1" colspan="1">C</td><td align="center" rowspan="1" colspan="1">T</td><td align="center" rowspan="1" colspan="1">
.</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">Moderate</td><td align="center" rowspan="1" colspan="1">0/0</td><td align="center" rowspan="1" colspan="1">175</td><td align="center" rowspan="1" colspan="1">184,0</td><td align="center" rowspan="1" colspan="1">99</td><td align="center" rowspan="1" colspan="1">103</td><td align="center" rowspan="1" colspan="1">108,0</td><td align="center" rowspan="1" colspan="1">99</td><td align="center" rowspan="1" colspan="1">0/1</td><td align="center" rowspan="1" colspan="1">133</td><td align="center" rowspan="1" colspan="1">79,68</td><td align="center" rowspan="1" colspan="1">99</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>3_89259200_T_EPHA3</bold>
</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">89259200</td><td align="center" rowspan="1" colspan="1">C</td><td align="center" rowspan="1" colspan="1">T</td><td align="center" rowspan="1" colspan="1">.</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">Moderate</td><td align="center" rowspan="1" colspan="1">0/0</td><td align="center" rowspan="1" colspan="1">43</td><td align="center" rowspan="1" colspan="1">45,0</td><td align="center" rowspan="1" colspan="1">99</td><td align="center" rowspan="1" colspan="1">117</td><td align="center" rowspan="1" colspan="1">123,0</td><td align="center" rowspan="1" colspan="1">99</td><td align="center" rowspan="1" colspan="1">0/1</td><td align="center" rowspan="1" colspan="1">72</td><td align="center" rowspan="1" colspan="1">30,48</td><td align="center" rowspan="1" colspan="1">99</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>1_51204545_C_FAF1</bold>
</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">51204545</td><td align="center" rowspan="1" colspan="1">T</td><td align="center" rowspan="1" colspan="1">C</td><td align="center" rowspan="1" colspan="1">.</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">Moderate</td><td align="center" rowspan="1" colspan="1">0/0</td><td align="center" rowspan="1" colspan="1">87</td><td align="center" rowspan="1" colspan="1">91,0</td><td align="center" rowspan="1" colspan="1">99</td><td align="center" rowspan="1" colspan="1">108</td><td align="center" rowspan="1" colspan="1">113,0</td><td align="center" rowspan="1" colspan="1">99</td><td align="center" rowspan="1" colspan="1">0/1</td><td align="center" rowspan="1" colspan="1">85</td><td align="center" rowspan="1" colspan="1">66,27</td><td align="center" rowspan="1" colspan="1">99</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>12_30834620_A_IPO8</bold>
</td><td align="center" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">30834620</td><td align="center" rowspan="1" colspan="1">C</td><td align="center" rowspan="1" colspan="1">A</td><td align="center" rowspan="1" colspan="1">.</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">Moderate</td><td align="center" rowspan="1" colspan="1">0/0</td><td align="center" rowspan="1" colspan="1">68</td><td align="center" rowspan="1" colspan="1">71,2</td><td align="center" rowspan="1" colspan="1">99</td><td align="center" rowspan="1" colspan="1">120</td><td align="center" rowspan="1" colspan="1">126,0</td><td align="center" rowspan="1" colspan="1">99</td><td align="center" rowspan="1" colspan="1">0/1</td><td align="center" rowspan="1" colspan="1">80</td><td align="center" rowspan="1" colspan="1">70,18</td><td align="center" rowspan="1" colspan="1">99</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>11_101834425_A_KIAA1377</bold>
</td><td align="center" rowspan="1" colspan="1">11</td><td align="center" rowspan="1" colspan="1">101834425</td><td align="center" rowspan="1" colspan="1">G</td><td align="center" rowspan="1" colspan="1">A</td><td align="center" rowspan="1" colspan="1">.</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">Moderate</td><td align="center" rowspan="1" colspan="1">0/0</td><td align="center" rowspan="1" colspan="1">36</td><td align="center" rowspan="1" colspan="1">37,1</td><td align="center" rowspan="1" colspan="1">90</td><td align="center" rowspan="1" colspan="1">67</td><td align="center" rowspan="1" colspan="1">70,0</td><td align="center" rowspan="1" colspan="1">99</td><td align="center" rowspan="1" colspan="1">0/1</td><td align="center" rowspan="1" colspan="1">86</td><td align="center" rowspan="1" colspan="1">31,63</td><td align="center" rowspan="1" colspan="1">99</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>4_41682102_C_LIMCH1</bold>
</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">41682102</td><td align="center" rowspan="1" colspan="1">G</td><td align="center" rowspan="1" colspan="1">C</td><td align="center" rowspan="1" colspan="1">.</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">0.000077</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0.000227</td><td align="center" rowspan="1" colspan="1">Moderate</td><td align="center" rowspan="1" colspan="1">0/0</td><td align="center" rowspan="1" colspan="1">71</td><td align="center" rowspan="1" colspan="1">74,0</td><td align="center" rowspan="1" colspan="1">99</td><td align="center" rowspan="1" colspan="1">96</td><td align="center" rowspan="1" colspan="1">101,0</td><td align="center" rowspan="1" colspan="1">99</td><td align="center" rowspan="1" colspan="1">0/1</td><td align="center" rowspan="1" colspan="1">153</td><td align="center" rowspan="1" colspan="1">120,49</td><td align="center" rowspan="1" colspan="1">99</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>5_36985326_G_NIPBL</bold>
</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">36985326</td><td align="center" rowspan="1" colspan="1">A</td><td align="center" rowspan="1" colspan="1">G</td><td align="center" rowspan="1" colspan="1">.</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">Moderate</td><td align="center" rowspan="1" colspan="1">0/0</td><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">6,0</td><td align="center" rowspan="1" colspan="1">18</td><td align="center" rowspan="1" colspan="1">35</td><td align="center" rowspan="1" colspan="1">36,0</td><td align="center" rowspan="1" colspan="1">81</td><td align="center" rowspan="1" colspan="1">0/1</td><td align="center" rowspan="1" colspan="1">20</td><td align="center" rowspan="1" colspan="1">10,12</td><td align="center" rowspan="1" colspan="1">99</td></tr><tr><td align="left" rowspan="1" colspan="1">3_77623789_A_ROBO2</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">77623789</td><td align="center" rowspan="1" colspan="1">AG</td><td align="center" rowspan="1" colspan="1">A</td><td align="center" rowspan="1" colspan="1">.</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">High</td><td align="center" rowspan="1" colspan="1">0/0</td><td align="center" rowspan="1" colspan="1">22</td><td align="center" rowspan="1" colspan="1">NA</td><td align="center" rowspan="1" colspan="1">54</td><td align="center" rowspan="1" colspan="1">29</td><td align="center" rowspan="1" colspan="1">NA</td><td align="center" rowspan="1" colspan="1">87</td><td align="center" rowspan="1" colspan="1">0/1</td><td align="center" rowspan="1" colspan="1">37</td><td align="center" rowspan="1" colspan="1">NA</td><td align="center" rowspan="1" colspan="1">99</td></tr><tr><td align="left" rowspan="1" colspan="1">2_217300095_A_SMARCAL1</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">217300095</td><td align="center" rowspan="1" colspan="1">ATTGCATCAACGTCGTGG</td><td align="center" rowspan="1" colspan="1">A</td><td align="center" rowspan="1" colspan="1">.</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">High</td><td align="center" rowspan="1" colspan="1">0/0</td><td align="center" rowspan="1" colspan="1">95</td><td align="center" rowspan="1" colspan="1">NA</td><td align="center" rowspan="1" colspan="1">99</td><td align="center" rowspan="1" colspan="1">122</td><td align="center" rowspan="1" colspan="1">NA</td><td align="center" rowspan="1" colspan="1">99</td><td align="center" rowspan="1" colspan="1">0/1</td><td align="center" rowspan="1" colspan="1">99</td><td align="center" rowspan="1" colspan="1">NA</td><td align="center" rowspan="1" colspan="1">99</td></tr><tr><td align="left" rowspan="1" colspan="1">2_152236045_T_TAA_TNFAIP6</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">152236045</td><td align="center" rowspan="1" colspan="1">TA</td><td align="center" rowspan="1" colspan="1">T/TAA</td><td align="center" rowspan="1" colspan="1">rs35060021</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">High</td><td align="center" rowspan="1" colspan="1">0/2</td><td align="center" rowspan="1" colspan="1">19</td><td align="center" rowspan="1" colspan="1">NA</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">24</td><td align="center" rowspan="1" colspan="1">NA</td><td align="center" rowspan="1" colspan="1">57</td><td align="center" rowspan="1" colspan="1">0/1</td><td align="center" rowspan="1" colspan="1">17</td><td align="center" rowspan="1" colspan="1">NA</td><td align="center" rowspan="1" colspan="1">38</td></tr><tr><td align="left" rowspan="1" colspan="1">3_52020669_T_ACY1</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">52020669</td><td align="center" rowspan="1" colspan="1">G</td><td align="center" rowspan="1" colspan="1">T</td><td align="center" rowspan="1" colspan="1">.</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">Moderate</td><td align="center" rowspan="1" colspan="1">0/0</td><td align="center" rowspan="1" colspan="1">130</td><td align="center" rowspan="1" colspan="1">136,0</td><td align="center" rowspan="1" colspan="1">99</td><td align="center" rowspan="1" colspan="1">86</td><td align="center" rowspan="1" colspan="1">90,0</td><td align="center" rowspan="1" colspan="1">99</td><td align="center" rowspan="1" colspan="1">0/1</td><td align="center" rowspan="1" colspan="1">80</td><td align="center" rowspan="1" colspan="1">45,43</td><td align="center" rowspan="1" colspan="1">99</td></tr><tr><td align="left" rowspan="1" colspan="1">9_117130734_G_AKNA</td><td align="center" rowspan="1" colspan="1">9</td><td align="center" rowspan="1" colspan="1">117130734</td><td align="center" rowspan="1" colspan="1">C</td><td align="center" rowspan="1" colspan="1">G</td><td align="center" rowspan="1" colspan="1">.</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">Moderate</td><td align="center" rowspan="1" colspan="1">0/0</td><td align="center" rowspan="1" colspan="1">27</td><td align="center" rowspan="1" colspan="1">28,0</td><td align="center" rowspan="1" colspan="1">78</td><td align="center" rowspan="1" colspan="1">30</td><td align="center" rowspan="1" colspan="1">31,0</td><td align="center" rowspan="1" colspan="1">90</td><td align="center" rowspan="1" colspan="1">0/1</td><td align="center" rowspan="1" colspan="1">50</td><td align="center" rowspan="1" colspan="1">30,24</td><td align="center" rowspan="1" colspan="1">99</td></tr><tr><td align="left" rowspan="1" colspan="1">12_6030354_A_ANO2</td><td align="center" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">6030354</td><td align="center" rowspan="1" colspan="1">C</td><td align="center" rowspan="1" colspan="1">A</td><td align="center" rowspan="1" colspan="1">.</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">Moderate</td><td align="center" rowspan="1" colspan="1">0/0</td><td align="center" rowspan="1" colspan="1">101</td><td align="center" rowspan="1" colspan="1">106,0</td><td align="center" rowspan="1" colspan="1">99</td><td align="center" rowspan="1" colspan="1">114</td><td align="center" rowspan="1" colspan="1">120,0</td><td align="center" rowspan="1" colspan="1">99</td><td align="center" rowspan="1" colspan="1">0/1</td><td align="center" rowspan="1" colspan="1">135</td><td align="center" rowspan="1" colspan="1">104,45</td><td align="center" rowspan="1" colspan="1">99</td></tr><tr><td align="left" rowspan="1" colspan="1">18_10487667_A_APCDD1</td><td align="center" rowspan="1" colspan="1">18</td><td align="center" rowspan="1" colspan="1">10487667</td><td align="center" rowspan="1" colspan="1">G</td><td align="center" rowspan="1" colspan="1">A</td><td align="center" rowspan="1" colspan="1">.</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">Moderate</td><td align="center" rowspan="1" colspan="1">0/0</td><td align="center" rowspan="1" colspan="1">43</td><td align="center" rowspan="1" colspan="1">45,0</td><td align="center" rowspan="1" colspan="1">99</td><td align="center" rowspan="1" colspan="1">38</td><td align="center" rowspan="1" colspan="1">40,0</td><td align="center" rowspan="1" colspan="1">99</td><td align="center" rowspan="1" colspan="1">0/1</td><td align="center" rowspan="1" colspan="1">50</td><td align="center" rowspan="1" colspan="1">38,16</td><td align="center" rowspan="1" colspan="1">99</td></tr><tr><td align="left" rowspan="1" colspan="1">7_34118560_C_BMPER</td><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">34118560</td><td align="center" rowspan="1" colspan="1">G</td><td align="center" rowspan="1" colspan="1">C</td><td align="center" rowspan="1" colspan="1">.</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">Moderate</td><td align="center" rowspan="1" colspan="1">0/0</td><td align="center" rowspan="1" colspan="1">69</td><td align="center" rowspan="1" colspan="1">72,0</td><td align="center" rowspan="1" colspan="1">99</td><td align="center" rowspan="1" colspan="1">101</td><td align="center" rowspan="1" colspan="1">106,0</td><td align="center" rowspan="1" colspan="1">99</td><td align="center" rowspan="1" colspan="1">0/1</td><td align="center" rowspan="1" colspan="1">71</td><td align="center" rowspan="1" colspan="1">63,14</td><td align="center" rowspan="1" colspan="1">99</td></tr><tr><td align="left" rowspan="1" colspan="1">15_24921273_T_C15orf2</td><td align="center" rowspan="1" colspan="1">15</td><td align="center" rowspan="1" colspan="1">24921273</td><td align="center" rowspan="1" colspan="1">G</td><td align="center" rowspan="1" colspan="1">T</td><td align="center" rowspan="1" colspan="1">.</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">Moderate</td><td align="center" rowspan="1" colspan="1">0/0</td><td align="center" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">12,0</td><td align="center" rowspan="1" colspan="1">36</td><td align="center" rowspan="1" colspan="1">38</td><td align="center" rowspan="1" colspan="1">39,0</td><td align="center" rowspan="1" colspan="1">99</td><td align="center" rowspan="1" colspan="1">0/1</td><td align="center" rowspan="1" colspan="1">26</td><td align="center" rowspan="1" colspan="1">22,6</td><td align="center" rowspan="1" colspan="1">99</td></tr><tr><td align="left" rowspan="1" colspan="1">19_54483249_C_CACNG8</td><td align="center" rowspan="1" colspan="1">19</td><td align="center" rowspan="1" colspan="1">54483249</td><td align="center" rowspan="1" colspan="1">T</td><td align="center" rowspan="1" colspan="1">C</td><td align="center" rowspan="1" colspan="1">.</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">Moderate</td><td align="center" rowspan="1" colspan="1">0/0</td><td align="center" rowspan="1" colspan="1">147</td><td align="center" rowspan="1" colspan="1">154,0</td><td align="center" rowspan="1" colspan="1">99</td><td align="center" rowspan="1" colspan="1">103</td><td align="center" rowspan="1" colspan="1">108,0</td><td align="center" rowspan="1" colspan="1">99</td><td align="center" rowspan="1" colspan="1">0/1</td><td align="center" rowspan="1" colspan="1">152</td><td align="center" rowspan="1" colspan="1">136,32</td><td align="center" rowspan="1" colspan="1">99</td></tr><tr><td align="left" rowspan="1" colspan="1">10_16893265_C_CUBN</td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">16893265</td><td align="center" rowspan="1" colspan="1">G</td><td align="center" rowspan="1" colspan="1">C</td><td align="center" rowspan="1" colspan="1">.</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">Moderate</td><td align="center" rowspan="1" colspan="1">0/0</td><td align="center" rowspan="1" colspan="1">57</td><td align="center" rowspan="1" colspan="1">60,0</td><td align="center" rowspan="1" colspan="1">99</td><td align="center" rowspan="1" colspan="1">90</td><td align="center" rowspan="1" colspan="1">94,0</td><td align="center" rowspan="1" colspan="1">99</td><td align="center" rowspan="1" colspan="1">0/1</td><td align="center" rowspan="1" colspan="1">40</td><td align="center" rowspan="1" colspan="1">34,10</td><td align="center" rowspan="1" colspan="1">99</td></tr><tr><td align="left" rowspan="1" colspan="1">7_148489854_C_CUL1</td><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">148489854</td><td align="center" rowspan="1" colspan="1">A</td><td align="center" rowspan="1" colspan="1">C</td><td align="center" rowspan="1" colspan="1">.</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">Moderate</td><td align="center" rowspan="1" colspan="1">0/0</td><td align="center" rowspan="1" colspan="1">73</td><td align="center" rowspan="1" colspan="1">76,0</td><td align="center" rowspan="1" colspan="1">99</td><td align="center" rowspan="1" colspan="1">65</td><td align="center" rowspan="1" colspan="1">68,0</td><td align="center" rowspan="1" colspan="1">99</td><td align="center" rowspan="1" colspan="1">0/1</td><td align="center" rowspan="1" colspan="1">57</td><td align="center" rowspan="1" colspan="1">42,21</td><td align="center" rowspan="1" colspan="1">99</td></tr><tr><td align="left" rowspan="1" colspan="1">17_41566894_C_DHX8</td><td align="center" rowspan="1" colspan="1">17</td><td align="center" rowspan="1" colspan="1">41566894</td><td align="center" rowspan="1" colspan="1">G</td><td align="center" rowspan="1" colspan="1">C</td><td align="center" rowspan="1" colspan="1">.</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">Moderate</td><td align="center" rowspan="1" colspan="1">0/0</td><td align="center" rowspan="1" colspan="1">106</td><td align="center" rowspan="1" colspan="1">111,0</td><td align="center" rowspan="1" colspan="1">99</td><td align="center" rowspan="1" colspan="1">88</td><td align="center" rowspan="1" colspan="1">92,0</td><td align="center" rowspan="1" colspan="1">99</td><td align="center" rowspan="1" colspan="1">0/1</td><td align="center" rowspan="1" colspan="1">124</td><td align="center" rowspan="1" colspan="1">94,42</td><td align="center" rowspan="1" colspan="1">99</td></tr><tr><td align="left" rowspan="1" colspan="1">20_61512358_T_DIDO1</td><td align="center" rowspan="1" colspan="1">20</td><td align="center" rowspan="1" colspan="1">61512358</td><td align="center" rowspan="1" colspan="1">G</td><td align="center" rowspan="1" colspan="1">T</td><td align="center" rowspan="1" colspan="1">rs73304513</td><td align="center" rowspan="1" colspan="1">0.0417</td><td align="center" rowspan="1" colspan="1">0.045932</td><td align="center" rowspan="1" colspan="1">0.000838</td><td align="center" rowspan="1" colspan="1">0.135456</td><td align="center" rowspan="1" colspan="1">Moderate</td><td align="center" rowspan="1" colspan="1">0/0</td><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">0,0</td><td align="center" rowspan="1" colspan="1">18</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">0,0</td><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">0/1</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">0,0</td><td align="center" rowspan="1" colspan="1">21</td></tr><tr><td align="left" rowspan="1" colspan="1">16_23703526_A_ERN2</td><td align="center" rowspan="1" colspan="1">16</td><td align="center" rowspan="1" colspan="1">23703526</td><td align="center" rowspan="1" colspan="1">G</td><td align="center" rowspan="1" colspan="1">A</td><td align="center" rowspan="1" colspan="1">.</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">Moderate</td><td align="center" rowspan="1" colspan="1">0/0</td><td align="center" rowspan="1" colspan="1">81</td><td align="center" rowspan="1" colspan="1">85,0</td><td align="center" rowspan="1" colspan="1">99</td><td align="center" rowspan="1" colspan="1">98</td><td align="center" rowspan="1" colspan="1">103,0</td><td align="center" rowspan="1" colspan="1">99</td><td align="center" rowspan="1" colspan="1">0/1</td><td align="center" rowspan="1" colspan="1">91</td><td align="center" rowspan="1" colspan="1">60,41</td><td align="center" rowspan="1" colspan="1">99</td></tr><tr><td align="left" rowspan="1" colspan="1">3_197880164_G_FAM157A</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">197880164</td><td align="center" rowspan="1" colspan="1">GCAGCAGCAA</td><td align="center" rowspan="1" colspan="1">G</td><td align="center" rowspan="1" colspan="1">.</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">Moderate</td><td align="center" rowspan="1" colspan="1">0/0</td><td align="center" rowspan="1" colspan="1">21</td><td align="center" rowspan="1" colspan="1">NA</td><td align="center" rowspan="1" colspan="1">25</td><td align="center" rowspan="1" colspan="1">25</td><td align="center" rowspan="1" colspan="1">NA</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">0/1</td><td align="center" rowspan="1" colspan="1">31</td><td align="center" rowspan="1" colspan="1">NA</td><td align="center" rowspan="1" colspan="1">6</td></tr><tr><td align="left" rowspan="1" colspan="1">14_45644287_G_FANCM</td><td align="center" rowspan="1" colspan="1">14</td><td align="center" rowspan="1" colspan="1">45644287</td><td align="center" rowspan="1" colspan="1">A</td><td align="center" rowspan="1" colspan="1">G</td><td align="center" rowspan="1" colspan="1">.</td><td align="center" rowspan="1" colspan="1">0.0009</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">Moderate</td><td align="center" rowspan="1" colspan="1">0/0</td><td align="center" rowspan="1" colspan="1">13</td><td align="center" rowspan="1" colspan="1">13,0</td><td align="center" rowspan="1" colspan="1">33</td><td align="center" rowspan="1" colspan="1">31</td><td align="center" rowspan="1" colspan="1">32,0</td><td align="center" rowspan="1" colspan="1">87</td><td align="center" rowspan="1" colspan="1">0/1</td><td align="center" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">10,2</td><td align="center" rowspan="1" colspan="1">14</td></tr><tr><td align="left" rowspan="1" colspan="1">1_89637524_C_GBP7</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">89637524</td><td align="center" rowspan="1" colspan="1">G</td><td align="center" rowspan="1" colspan="1">C</td><td align="center" rowspan="1" colspan="1">.</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">Moderate</td><td align="center" rowspan="1" colspan="1">0/0</td><td align="center" rowspan="1" colspan="1">171</td><td align="center" rowspan="1" colspan="1">179,0</td><td align="center" rowspan="1" colspan="1">99</td><td align="center" rowspan="1" colspan="1">201</td><td align="center" rowspan="1" colspan="1">211,0</td><td align="center" rowspan="1" colspan="1">99</td><td align="center" rowspan="1" colspan="1">0/1</td><td align="center" rowspan="1" colspan="1">206</td><td align="center" rowspan="1" colspan="1">161,67</td><td align="center" rowspan="1" colspan="1">99</td></tr><tr><td align="left" rowspan="1" colspan="1">7_42003933_C_GLI3</td><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">42003933</td><td align="center" rowspan="1" colspan="1">G</td><td align="center" rowspan="1" colspan="1">C</td><td align="center" rowspan="1" colspan="1">.</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">Moderate</td><td align="center" rowspan="1" colspan="1">0/0</td><td align="center" rowspan="1" colspan="1">87</td><td align="center" rowspan="1" colspan="1">91,0</td><td align="center" rowspan="1" colspan="1">99</td><td align="center" rowspan="1" colspan="1">81</td><td align="center" rowspan="1" colspan="1">85,0</td><td align="center" rowspan="1" colspan="1">99</td><td align="center" rowspan="1" colspan="1">0/1</td><td align="center" rowspan="1" colspan="1">85</td><td align="center" rowspan="1" colspan="1">61,32</td><td align="center" rowspan="1" colspan="1">99</td></tr><tr><td align="left" rowspan="1" colspan="1">17_4837170_T_GP1BA</td><td align="center" rowspan="1" colspan="1">17</td><td align="center" rowspan="1" colspan="1">4837170</td><td align="center" rowspan="1" colspan="1">C</td><td align="center" rowspan="1" colspan="1">T</td><td align="center" rowspan="1" colspan="1">.</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">Moderate</td><td align="center" rowspan="1" colspan="1">0/0</td><td align="center" rowspan="1" colspan="1">16</td><td align="center" rowspan="1" colspan="1">16,0</td><td align="center" rowspan="1" colspan="1">45</td><td align="center" rowspan="1" colspan="1">9</td><td align="center" rowspan="1" colspan="1">9,0</td><td align="center" rowspan="1" colspan="1">15</td><td align="center" rowspan="1" colspan="1">0/1</td><td align="center" rowspan="1" colspan="1">11</td><td align="center" rowspan="1" colspan="1">10,1</td><td align="center" rowspan="1" colspan="1">1</td></tr><tr><td align="left" rowspan="1" colspan="1">14_24635161_G_IRF9</td><td align="center" rowspan="1" colspan="1">14</td><td align="center" rowspan="1" colspan="1">24635161</td><td align="center" rowspan="1" colspan="1">T</td><td align="center" rowspan="1" colspan="1">G</td><td align="center" rowspan="1" colspan="1">.</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">Moderate</td><td align="center" rowspan="1" colspan="1">0/0</td><td align="center" rowspan="1" colspan="1">66</td><td align="center" rowspan="1" colspan="1">69,0</td><td align="center" rowspan="1" colspan="1">99</td><td align="center" rowspan="1" colspan="1">43</td><td align="center" rowspan="1" colspan="1">45,0</td><td align="center" rowspan="1" colspan="1">99</td><td align="center" rowspan="1" colspan="1">0/1</td><td align="center" rowspan="1" colspan="1">36</td><td align="center" rowspan="1" colspan="1">25,13</td><td align="center" rowspan="1" colspan="1">99</td></tr><tr><td align="left" rowspan="1" colspan="1">15_42133096_A_JMJD7-PLA2G4B</td><td align="center" rowspan="1" colspan="1">15</td><td align="center" rowspan="1" colspan="1">42133096</td><td align="center" rowspan="1" colspan="1">G</td><td align="center" rowspan="1" colspan="1">A</td><td align="center" rowspan="1" colspan="1">.</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">Moderate</td><td align="center" rowspan="1" colspan="1">0/0</td><td align="center" rowspan="1" colspan="1">111</td><td align="center" rowspan="1" colspan="1">116,0</td><td align="center" rowspan="1" colspan="1">99</td><td align="center" rowspan="1" colspan="1">75</td><td align="center" rowspan="1" colspan="1">78,0</td><td align="center" rowspan="1" colspan="1">99</td><td align="center" rowspan="1" colspan="1">0/1</td><td align="center" rowspan="1" colspan="1">80</td><td align="center" rowspan="1" colspan="1">74,14</td><td align="center" rowspan="1" colspan="1">92</td></tr><tr><td align="left" rowspan="1" colspan="1">17_40271678_A_KAT2A</td><td align="center" rowspan="1" colspan="1">17</td><td align="center" rowspan="1" colspan="1">40271678</td><td align="center" rowspan="1" colspan="1">G</td><td align="center" rowspan="1" colspan="1">A</td><td align="center" rowspan="1" colspan="1">.</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">Moderate</td><td align="center" rowspan="1" colspan="1">0/0</td><td align="center" rowspan="1" colspan="1">65</td><td align="center" rowspan="1" colspan="1">68,0</td><td align="center" rowspan="1" colspan="1">99</td><td align="center" rowspan="1" colspan="1">58</td><td align="center" rowspan="1" colspan="1">61,0</td><td align="center" rowspan="1" colspan="1">99</td><td align="center" rowspan="1" colspan="1">0/1</td><td align="center" rowspan="1" colspan="1">56</td><td align="center" rowspan="1" colspan="1">30,32</td><td align="center" rowspan="1" colspan="1">99</td></tr><tr><td align="left" rowspan="1" colspan="1">8_73848894_G_KCNB2</td><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">73848894</td><td align="center" rowspan="1" colspan="1">A</td><td align="center" rowspan="1" colspan="1">G</td><td align="center" rowspan="1" colspan="1">.</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">Moderate</td><td align="center" rowspan="1" colspan="1">0/0</td><td align="center" rowspan="1" colspan="1">15</td><td align="center" rowspan="1" colspan="1">15,0</td><td align="center" rowspan="1" colspan="1">33</td><td align="center" rowspan="1" colspan="1">24</td><td align="center" rowspan="1" colspan="1">25,0</td><td align="center" rowspan="1" colspan="1">66</td><td align="center" rowspan="1" colspan="1">0/1</td><td align="center" rowspan="1" colspan="1">30</td><td align="center" rowspan="1" colspan="1">15,17</td><td align="center" rowspan="1" colspan="1">99</td></tr><tr><td align="left" rowspan="1" colspan="1">19_50827053_T_KCNC3</td><td align="center" rowspan="1" colspan="1">19</td><td align="center" rowspan="1" colspan="1">50827053</td><td align="center" rowspan="1" colspan="1">C</td><td align="center" rowspan="1" colspan="1">T</td><td align="center" rowspan="1" colspan="1">.</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">Moderate</td><td align="center" rowspan="1" colspan="1">0/0</td><td align="center" rowspan="1" colspan="1">220</td><td align="center" rowspan="1" colspan="1">231,0</td><td align="center" rowspan="1" colspan="1">99</td><td align="center" rowspan="1" colspan="1">136</td><td align="center" rowspan="1" colspan="1">143,0</td><td align="center" rowspan="1" colspan="1">99</td><td align="center" rowspan="1" colspan="1">0/1</td><td align="center" rowspan="1" colspan="1">160</td><td align="center" rowspan="1" colspan="1">130,46</td><td align="center" rowspan="1" colspan="1">99</td></tr><tr><td align="left" rowspan="1" colspan="1">17_21319069_A_KCNJ12</td><td align="center" rowspan="1" colspan="1">17</td><td align="center" rowspan="1" colspan="1">21319069</td><td align="center" rowspan="1" colspan="1">G</td><td align="center" rowspan="1" colspan="1">A</td><td align="center" rowspan="1" colspan="1">rs76265595</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">Moderate</td><td align="center" rowspan="1" colspan="1">0/0</td><td align="center" rowspan="1" colspan="1">23</td><td align="center" rowspan="1" colspan="1">24,1</td><td align="center" rowspan="1" colspan="1">63</td><td align="center" rowspan="1" colspan="1">43</td><td align="center" rowspan="1" colspan="1">43,4</td><td align="center" rowspan="1" colspan="1">40</td><td align="center" rowspan="1" colspan="1">0/1</td><td align="center" rowspan="1" colspan="1">28</td><td align="center" rowspan="1" colspan="1">25,5</td><td align="center" rowspan="1" colspan="1">60</td></tr><tr><td align="left" rowspan="1" colspan="1">12_53011932_C_KRT73</td><td align="center" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">53011932</td><td align="center" rowspan="1" colspan="1">T</td><td align="center" rowspan="1" colspan="1">C</td><td align="center" rowspan="1" colspan="1">.</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">Moderate</td><td align="center" rowspan="1" colspan="1">0/0</td><td align="center" rowspan="1" colspan="1">146</td><td align="center" rowspan="1" colspan="1">153,0</td><td align="center" rowspan="1" colspan="1">99</td><td align="center" rowspan="1" colspan="1">157</td><td align="center" rowspan="1" colspan="1">165,0</td><td align="center" rowspan="1" colspan="1">99</td><td align="center" rowspan="1" colspan="1">0/1</td><td align="center" rowspan="1" colspan="1">159</td><td align="center" rowspan="1" colspan="1">117,58</td><td align="center" rowspan="1" colspan="1">99</td></tr><tr><td align="left" rowspan="1" colspan="1">X_75004584_A_MAGEE2</td><td align="center" rowspan="1" colspan="1">X</td><td align="center" rowspan="1" colspan="1">75004584</td><td align="center" rowspan="1" colspan="1">C</td><td align="center" rowspan="1" colspan="1">A</td><td align="center" rowspan="1" colspan="1">.</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">Moderate</td><td align="center" rowspan="1" colspan="1">0/0</td><td align="center" rowspan="1" colspan="1">29</td><td align="center" rowspan="1" colspan="1">30,0</td><td align="center" rowspan="1" colspan="1">81</td><td align="center" rowspan="1" colspan="1">48</td><td align="center" rowspan="1" colspan="1">50,0</td><td align="center" rowspan="1" colspan="1">99</td><td align="center" rowspan="1" colspan="1">0/1</td><td align="center" rowspan="1" colspan="1">38</td><td align="center" rowspan="1" colspan="1">26,16</td><td align="center" rowspan="1" colspan="1">99</td></tr><tr><td align="left" rowspan="1" colspan="1">5_140182157_A_PCDHA3</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">140182157</td><td align="center" rowspan="1" colspan="1">G</td><td align="center" rowspan="1" colspan="1">A</td><td align="center" rowspan="1" colspan="1">.</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">Moderate</td><td align="center" rowspan="1" colspan="1">0/0</td><td align="center" rowspan="1" colspan="1">180</td><td align="center" rowspan="1" colspan="1">189,0</td><td align="center" rowspan="1" colspan="1">99</td><td align="center" rowspan="1" colspan="1">153</td><td align="center" rowspan="1" colspan="1">161,0</td><td align="center" rowspan="1" colspan="1">99</td><td align="center" rowspan="1" colspan="1">0/1</td><td align="center" rowspan="1" colspan="1">150</td><td align="center" rowspan="1" colspan="1">132,34</td><td align="center" rowspan="1" colspan="1">99</td></tr><tr><td align="left" rowspan="1" colspan="1">15_42133096_A_PLA2G4B</td><td align="center" rowspan="1" colspan="1">15</td><td align="center" rowspan="1" colspan="1">42133096</td><td align="center" rowspan="1" colspan="1">G</td><td align="center" rowspan="1" colspan="1">A</td><td align="center" rowspan="1" colspan="1">.</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">Moderate</td><td align="center" rowspan="1" colspan="1">0/0</td><td align="center" rowspan="1" colspan="1">111</td><td align="center" rowspan="1" colspan="1">116,0</td><td align="center" rowspan="1" colspan="1">99</td><td align="center" rowspan="1" colspan="1">75</td><td align="center" rowspan="1" colspan="1">78,0</td><td align="center" rowspan="1" colspan="1">99</td><td align="center" rowspan="1" colspan="1">0/1</td><td align="center" rowspan="1" colspan="1">80</td><td align="center" rowspan="1" colspan="1">74,14</td><td align="center" rowspan="1" colspan="1">92</td></tr><tr><td align="left" rowspan="1" colspan="1">10_96005840_C_PLCE1</td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">96005840</td><td align="center" rowspan="1" colspan="1">T</td><td align="center" rowspan="1" colspan="1">C</td><td align="center" rowspan="1" colspan="1">.</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">Moderate</td><td align="center" rowspan="1" colspan="1">0/0</td><td align="center" rowspan="1" colspan="1">81</td><td align="center" rowspan="1" colspan="1">85,1</td><td align="center" rowspan="1" colspan="1">99</td><td align="center" rowspan="1" colspan="1">73</td><td align="center" rowspan="1" colspan="1">76,2</td><td align="center" rowspan="1" colspan="1">99</td><td align="center" rowspan="1" colspan="1">0/1</td><td align="center" rowspan="1" colspan="1">87</td><td align="center" rowspan="1" colspan="1">55,40</td><td align="center" rowspan="1" colspan="1">99</td></tr><tr><td align="left" rowspan="1" colspan="1">1_166816805_G_POGK</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">166816805</td><td align="center" rowspan="1" colspan="1">C</td><td align="center" rowspan="1" colspan="1">G</td><td align="center" rowspan="1" colspan="1">.</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">Moderate</td><td align="center" rowspan="1" colspan="1">0/0</td><td align="center" rowspan="1" colspan="1">84</td><td align="center" rowspan="1" colspan="1">88,0</td><td align="center" rowspan="1" colspan="1">99</td><td align="center" rowspan="1" colspan="1">82</td><td align="center" rowspan="1" colspan="1">86,0</td><td align="center" rowspan="1" colspan="1">99</td><td align="center" rowspan="1" colspan="1">0/1</td><td align="center" rowspan="1" colspan="1">63</td><td align="center" rowspan="1" colspan="1">49,20</td><td align="center" rowspan="1" colspan="1">99</td></tr><tr><td align="left" rowspan="1" colspan="1">12_111020739_T_PPTC7</td><td align="center" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">111020739</td><td align="center" rowspan="1" colspan="1">TCGC</td><td align="center" rowspan="1" colspan="1">T</td><td align="center" rowspan="1" colspan="1">rs71083132</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">Moderate</td><td align="center" rowspan="1" colspan="1">0/0</td><td align="center" rowspan="1" colspan="1">18</td><td align="center" rowspan="1" colspan="1">NA</td><td align="center" rowspan="1" colspan="1">30</td><td align="center" rowspan="1" colspan="1">14</td><td align="center" rowspan="1" colspan="1">NA</td><td align="center" rowspan="1" colspan="1">18</td><td align="center" rowspan="1" colspan="1">0/1</td><td align="center" rowspan="1" colspan="1">19</td><td align="center" rowspan="1" colspan="1">NA</td><td align="center" rowspan="1" colspan="1">10</td></tr><tr><td align="left" rowspan="1" colspan="1">19_804293_A_PTBP1</td><td align="center" rowspan="1" colspan="1">19</td><td align="center" rowspan="1" colspan="1">804293</td><td align="center" rowspan="1" colspan="1">C</td><td align="center" rowspan="1" colspan="1">A</td><td align="center" rowspan="1" colspan="1">.</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">Moderate</td><td align="center" rowspan="1" colspan="1">0/0</td><td align="center" rowspan="1" colspan="1">120</td><td align="center" rowspan="1" colspan="1">126,1</td><td align="center" rowspan="1" colspan="1">99</td><td align="center" rowspan="1" colspan="1">71</td><td align="center" rowspan="1" colspan="1">74,1</td><td align="center" rowspan="1" colspan="1">99</td><td align="center" rowspan="1" colspan="1">0/1</td><td align="center" rowspan="1" colspan="1">75</td><td align="center" rowspan="1" colspan="1">53,30</td><td align="center" rowspan="1" colspan="1">99</td></tr><tr><td align="left" rowspan="1" colspan="1">7_156451175_C_RNF32</td><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">156451175</td><td align="center" rowspan="1" colspan="1">G</td><td align="center" rowspan="1" colspan="1">C</td><td align="center" rowspan="1" colspan="1">.</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">Moderate</td><td align="center" rowspan="1" colspan="1">0/0</td><td align="center" rowspan="1" colspan="1">55</td><td align="center" rowspan="1" colspan="1">57,0</td><td align="center" rowspan="1" colspan="1">99</td><td align="center" rowspan="1" colspan="1">67</td><td align="center" rowspan="1" colspan="1">70,0</td><td align="center" rowspan="1" colspan="1">99</td><td align="center" rowspan="1" colspan="1">0/1</td><td align="center" rowspan="1" colspan="1">59</td><td align="center" rowspan="1" colspan="1">42,23</td><td align="center" rowspan="1" colspan="1">99</td></tr><tr><td align="left" rowspan="1" colspan="1">3_52020669_T_RP11-155D18.11</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">52020669</td><td align="center" rowspan="1" colspan="1">G</td><td align="center" rowspan="1" colspan="1">T</td><td align="center" rowspan="1" colspan="1">.</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">Moderate</td><td align="center" rowspan="1" colspan="1">0/0</td><td align="center" rowspan="1" colspan="1">130</td><td align="center" rowspan="1" colspan="1">136,0</td><td align="center" rowspan="1" colspan="1">99</td><td align="center" rowspan="1" colspan="1">86</td><td align="center" rowspan="1" colspan="1">90,0</td><td align="center" rowspan="1" colspan="1">99</td><td align="center" rowspan="1" colspan="1">0/1</td><td align="center" rowspan="1" colspan="1">80</td><td align="center" rowspan="1" colspan="1">45,43</td><td align="center" rowspan="1" colspan="1">99</td></tr><tr><td align="left" rowspan="1" colspan="1">21_43838624_T_UBASH3A</td><td align="center" rowspan="1" colspan="1">21</td><td align="center" rowspan="1" colspan="1">43838624</td><td align="center" rowspan="1" colspan="1">G</td><td align="center" rowspan="1" colspan="1">T</td><td align="center" rowspan="1" colspan="1">.</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">Moderate</td><td align="center" rowspan="1" colspan="1">0/0</td><td align="center" rowspan="1" colspan="1">70</td><td align="center" rowspan="1" colspan="1">73,0</td><td align="center" rowspan="1" colspan="1">99</td><td align="center" rowspan="1" colspan="1">45</td><td align="center" rowspan="1" colspan="1">47,0</td><td align="center" rowspan="1" colspan="1">99</td><td align="center" rowspan="1" colspan="1">0/1</td><td align="center" rowspan="1" colspan="1">89</td><td align="center" rowspan="1" colspan="1">76,21</td><td align="center" rowspan="1" colspan="1">99</td></tr><tr><td align="left" rowspan="1" colspan="1">19_58773857_A_ZNF544</td><td align="center" rowspan="1" colspan="1">19</td><td align="center" rowspan="1" colspan="1">58773857</td><td align="center" rowspan="1" colspan="1">G</td><td align="center" rowspan="1" colspan="1">A</td><td align="center" rowspan="1" colspan="1">.</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">Moderate</td><td align="center" rowspan="1" colspan="1">0/0</td><td align="center" rowspan="1" colspan="1">46</td><td align="center" rowspan="1" colspan="1">48,0</td><td align="center" rowspan="1" colspan="1">99</td><td align="center" rowspan="1" colspan="1">43</td><td align="center" rowspan="1" colspan="1">45,0</td><td align="center" rowspan="1" colspan="1">99</td><td align="center" rowspan="1" colspan="1">0/1</td><td align="center" rowspan="1" colspan="1">71</td><td align="center" rowspan="1" colspan="1">51,26</td><td align="center" rowspan="1" colspan="1">99</td></tr><tr><td align="left" rowspan="1" colspan="1">5_16465723_C_ZNF622</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">16465723</td><td align="center" rowspan="1" colspan="1">T</td><td align="center" rowspan="1" colspan="1">C</td><td align="center" rowspan="1" colspan="1">.</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">Moderate</td><td align="center" rowspan="1" colspan="1">0/0</td><td align="center" rowspan="1" colspan="1">17</td><td align="center" rowspan="1" colspan="1">17,0</td><td align="center" rowspan="1" colspan="1">39</td><td align="center" rowspan="1" colspan="1">14</td><td align="center" rowspan="1" colspan="1">14,0</td><td align="center" rowspan="1" colspan="1">33</td><td align="center" rowspan="1" colspan="1">0/1</td><td align="center" rowspan="1" colspan="1">27</td><td align="center" rowspan="1" colspan="1">14,15</td><td align="center" rowspan="1" colspan="1">99</td></tr></tbody></table></table-wrap><table-wrap-group id="tab2" orientation="portrait" position="float"><label>Table 2</label><caption><p>RNA induced in the tumor. (a) Transcripts overexpressed in the tumor compared to muscle but not bone. (b) Transcripts overexpressed in the tumor compared to bone but not muscle. (c) Transcripts most abundantly overexpressed in the tumor compared to muscle and bone. (d) as (a) but limited to genes expressed at least at the level of 1 unit in the reference tissue (muscle or bone). (e) Altered expression of genes associated with NF-<italic>&#x003ba;</italic>B activity. Analysis of RNASeq for the transcription factor NF-<italic>&#x003ba;</italic>B and gene products that regulate its activity. RNA messages that are selectively associated with the TNF pathway to NF-<italic>&#x003ba;</italic>B activation are marked with bold font. log<sub>2</sub>-fold change indicates the alteration in the tumor compared to muscle or bone (the respective columns indicate the expression level for each organ).</p></caption><table-wrap id="tab2a" orientation="portrait" position="anchor"><label>(a)</label><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">&#x02003;</th><th align="left" rowspan="1" colspan="1">&#x02009;</th><th align="center" rowspan="1" colspan="1">log<sub>2</sub>-fold change</th></tr><tr><th align="left" rowspan="1" colspan="1">&#x02009;</th><th align="center" rowspan="1" colspan="1">Muscle</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Tumor over muscle</td><td align="left" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">NRG1</td><td align="left" rowspan="1" colspan="1">Neuregulin 1</td><td align="center" rowspan="1" colspan="1">9.909</td></tr><tr><td align="left" rowspan="1" colspan="1">KSR2</td><td align="left" rowspan="1" colspan="1">Kinase suppressor of ras 2</td><td align="center" rowspan="1" colspan="1">9.675</td></tr><tr><td align="left" rowspan="1" colspan="1">MMP13</td><td align="left" rowspan="1" colspan="1">Matrix metallopeptidase 13 (collagenase 3)</td><td align="center" rowspan="1" colspan="1">9.528</td></tr><tr><td align="left" rowspan="1" colspan="1">SPP1</td><td align="left" rowspan="1" colspan="1">Secreted phosphoprotein 1</td><td align="center" rowspan="1" colspan="1">9.098</td></tr><tr><td align="left" rowspan="1" colspan="1">INHBA</td><td align="left" rowspan="1" colspan="1">Inhibin, beta A</td><td align="center" rowspan="1" colspan="1">8.570</td></tr><tr><td align="left" rowspan="1" colspan="1">COL11A1</td><td align="left" rowspan="1" colspan="1">Collagen, type XI, alpha 1</td><td align="center" rowspan="1" colspan="1">8.564</td></tr><tr><td align="left" rowspan="1" colspan="1">MMP9</td><td align="left" rowspan="1" colspan="1">Matrix metallopeptidase 9 (gelatinase B, 92&#x02009;kda gelatinase, 92&#x02009;kda type IV collagenase)</td><td align="center" rowspan="1" colspan="1">8.552</td></tr><tr><td align="left" rowspan="1" colspan="1">FBN2</td><td align="left" rowspan="1" colspan="1">Fibrillin 2</td><td align="center" rowspan="1" colspan="1">8.495</td></tr><tr><td align="left" rowspan="1" colspan="1">LRRC15</td><td align="left" rowspan="1" colspan="1">Leucine rich repeat containing 15</td><td align="center" rowspan="1" colspan="1">8.429</td></tr><tr><td align="left" rowspan="1" colspan="1">MMP11</td><td align="left" rowspan="1" colspan="1">Matrix metallopeptidase 11 (stromelysin 3)</td><td align="center" rowspan="1" colspan="1">8.336</td></tr><tr><td align="left" rowspan="1" colspan="1">E2F7</td><td align="left" rowspan="1" colspan="1">E2F transcription factor 7</td><td align="center" rowspan="1" colspan="1">8.314</td></tr><tr><td align="left" rowspan="1" colspan="1">PRAME</td><td align="left" rowspan="1" colspan="1">Preferentially expressed antigen in melanoma</td><td align="center" rowspan="1" colspan="1">8.179</td></tr><tr><td align="left" rowspan="1" colspan="1">PTK7</td><td align="left" rowspan="1" colspan="1">PTK7 protein tyrosine kinase 7</td><td align="center" rowspan="1" colspan="1">7.996</td></tr><tr><td align="left" rowspan="1" colspan="1">DSCAM</td><td align="left" rowspan="1" colspan="1">Down syndrome cell adhesion molecule</td><td align="center" rowspan="1" colspan="1">7.761</td></tr><tr><td align="left" rowspan="1" colspan="1">RGS4</td><td align="left" rowspan="1" colspan="1">Regulator of G-protein signaling 4</td><td align="center" rowspan="1" colspan="1">7.633</td></tr><tr><td align="left" rowspan="1" colspan="1">CNIH3</td><td align="left" rowspan="1" colspan="1">Cornichon homolog 3 (Drosophila)</td><td align="center" rowspan="1" colspan="1">7.632</td></tr><tr><td align="left" rowspan="1" colspan="1">OR10V1</td><td align="left" rowspan="1" colspan="1">Olfactory receptor, family 10, subfamily V, member 1</td><td align="center" rowspan="1" colspan="1">7.610</td></tr><tr><td align="left" rowspan="1" colspan="1">CEP55</td><td align="left" rowspan="1" colspan="1">Centrosomal protein 55&#x02009;kda</td><td align="center" rowspan="1" colspan="1">7.583</td></tr><tr><td align="left" rowspan="1" colspan="1">WNT5B</td><td align="left" rowspan="1" colspan="1">Wingless-type MMTV integration site family, member 5B</td><td align="center" rowspan="1" colspan="1">7.569</td></tr><tr><td align="left" rowspan="1" colspan="1">CA12</td><td align="left" rowspan="1" colspan="1">Carbonic anhydrase XII</td><td align="center" rowspan="1" colspan="1">7.520</td></tr><tr><td align="left" rowspan="1" colspan="1">GALNT5</td><td align="left" rowspan="1" colspan="1">UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 5 (GalNAc-T5)</td><td align="center" rowspan="1" colspan="1">7.517</td></tr></tbody></table></table-wrap><table-wrap id="tab2b" orientation="portrait" position="anchor"><label>(b)</label><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">&#x02003;</th><th align="left" rowspan="2" colspan="1">&#x02003;</th><th align="center" rowspan="1" colspan="1">log<sub>2</sub>-fold change</th></tr><tr><th align="center" rowspan="1" colspan="1">Bone</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Tumor over bone</td><td align="left" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">ROS1</td><td align="left" rowspan="1" colspan="1">c-ros oncogene 1, receptor tyrosine kinase</td><td align="center" rowspan="1" colspan="1">10.987</td></tr><tr><td align="left" rowspan="1" colspan="1">GREM1</td><td align="left" rowspan="1" colspan="1">Gremlin 1</td><td align="center" rowspan="1" colspan="1">10.604</td></tr><tr><td align="left" rowspan="1" colspan="1">NPTX1</td><td align="left" rowspan="1" colspan="1">Neuronal pentraxin I</td><td align="center" rowspan="1" colspan="1">8.813</td></tr><tr><td align="left" rowspan="1" colspan="1">GJB2</td><td align="left" rowspan="1" colspan="1">Gap junction protein, beta 2, 26&#x02009;kDa</td><td align="center" rowspan="1" colspan="1">8.597</td></tr><tr><td align="left" rowspan="1" colspan="1">CREB3L1</td><td align="left" rowspan="1" colspan="1">cAMP responsive element binding protein 3-like 1</td><td align="center" rowspan="1" colspan="1">8.506</td></tr><tr><td align="left" rowspan="1" colspan="1">KRT14</td><td align="left" rowspan="1" colspan="1">Keratin 14</td><td align="center" rowspan="1" colspan="1">8.351</td></tr><tr><td align="left" rowspan="1" colspan="1">SERPINE1</td><td align="left" rowspan="1" colspan="1">Serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1</td><td align="center" rowspan="1" colspan="1">8.288</td></tr><tr><td align="left" rowspan="1" colspan="1">HOXD10</td><td align="left" rowspan="1" colspan="1">Homeobox D10</td><td align="center" rowspan="1" colspan="1">8.105</td></tr><tr><td align="left" rowspan="1" colspan="1">ALPK2</td><td align="left" rowspan="1" colspan="1">Alpha-Kinase 2</td><td align="center" rowspan="1" colspan="1">7.783</td></tr><tr><td align="left" rowspan="1" colspan="1">POU3F2</td><td align="left" rowspan="1" colspan="1">POU class 3 homeobox 2</td><td align="center" rowspan="1" colspan="1">7.530</td></tr><tr><td align="left" rowspan="1" colspan="1">POSTN</td><td align="left" rowspan="1" colspan="1">Periostin, osteoblast specific factor</td><td align="center" rowspan="1" colspan="1">7.497</td></tr><tr><td align="left" rowspan="1" colspan="1">NAA11</td><td align="left" rowspan="1" colspan="1">N(alpha)-acetyltransferase 11, NatA catalytic subunit</td><td align="center" rowspan="1" colspan="1">7.439</td></tr><tr><td align="left" rowspan="1" colspan="1">STC2</td><td align="left" rowspan="1" colspan="1">Stanniocalcin 2</td><td align="center" rowspan="1" colspan="1">7.434</td></tr><tr><td align="left" rowspan="1" colspan="1">WNT5A</td><td align="left" rowspan="1" colspan="1">Wingless-type MMTV integration site family, member 5A</td><td align="center" rowspan="1" colspan="1">7.412</td></tr><tr><td align="left" rowspan="1" colspan="1">IGFN1</td><td align="left" rowspan="1" colspan="1">Immunoglobulin-like and fibronectin type III domain containing 1</td><td align="center" rowspan="1" colspan="1">7.387</td></tr><tr><td align="left" rowspan="1" colspan="1">STC1</td><td align="left" rowspan="1" colspan="1">Stanniocalcin 1</td><td align="center" rowspan="1" colspan="1">7.385</td></tr><tr><td align="left" rowspan="1" colspan="1">FAM180A</td><td align="left" rowspan="1" colspan="1">Family with sequence similarity 180, member A</td><td align="center" rowspan="1" colspan="1">7.315</td></tr><tr><td align="left" rowspan="1" colspan="1">KRT17</td><td align="left" rowspan="1" colspan="1">Keratin 17</td><td align="center" rowspan="1" colspan="1">7.305</td></tr><tr><td align="left" rowspan="1" colspan="1">BBOX1</td><td align="left" rowspan="1" colspan="1">Butyrobetaine (gamma), 2-oxoglutarate dioxygenase (gamma-butyrobetaine hydroxylase) 1</td><td align="center" rowspan="1" colspan="1">7.277</td></tr><tr><td align="left" rowspan="1" colspan="1">MAGEA1</td><td align="left" rowspan="1" colspan="1">Melanoma antigen family A, 1 (directs expression of antigen MZ2-E)</td><td align="center" rowspan="1" colspan="1">7.267</td></tr></tbody></table></table-wrap><table-wrap id="tab2c" orientation="portrait" position="anchor"><label>(c)</label><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">&#x02003;</th><th align="left" rowspan="1" colspan="1">&#x02009;</th><th align="center" colspan="2" rowspan="1">log<sub>2</sub>-fold change</th></tr><tr><th align="left" rowspan="1" colspan="1">&#x02009;</th><th align="center" rowspan="1" colspan="1">Muscle</th><th align="center" rowspan="1" colspan="1">Bone</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Tumor over bone/muscle</td><td align="left" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">ANO4</td><td align="left" rowspan="1" colspan="1">Anoctamin 4 (TMEM16D), transmembrane calcium-activated chloride channel, facilitates smooth muscle contraction</td><td align="center" rowspan="1" colspan="1">9.937</td><td align="center" rowspan="1" colspan="1">8.542</td></tr><tr><td align="left" rowspan="1" colspan="1">SLCO1B3</td><td align="left" rowspan="1" colspan="1">(OATP1B3) Solute carrier organic anion transporter family, member 1B3</td><td align="center" rowspan="1" colspan="1">9.569</td><td align="center" rowspan="1" colspan="1">9.760</td></tr><tr><td align="left" rowspan="1" colspan="1">MARCH4</td><td align="left" rowspan="1" colspan="1">Membrane-associated ring finger (C3HC4) 4, E3 ubiquitin ligase, located predominantly to the endoplasmic reticulum</td><td align="center" rowspan="1" colspan="1">9.538</td><td align="center" rowspan="1" colspan="1">7.406</td></tr><tr><td align="left" rowspan="1" colspan="1">IGF2BP1</td><td align="left" rowspan="1" colspan="1">Insulin-like growth factor 2 mRNA binding protein 1 binds to and stabilizes mRNA</td><td align="center" rowspan="1" colspan="1">9.440</td><td align="center" rowspan="1" colspan="1">9.631</td></tr><tr><td align="left" rowspan="1" colspan="1">ADAMTS16</td><td align="left" rowspan="1" colspan="1">ADAM metallopeptidase with thrombospondin type 1 motif, 16; zinc-dependent protease</td><td align="center" rowspan="1" colspan="1">9.260</td><td align="center" rowspan="1" colspan="1">8.450</td></tr><tr><td align="left" rowspan="1" colspan="1">SOX11</td><td align="left" rowspan="1" colspan="1">SRY (sex determining region Y)-box 11, important in brain development</td><td align="center" rowspan="1" colspan="1">9.178</td><td align="center" rowspan="1" colspan="1">9.954</td></tr><tr><td align="left" rowspan="1" colspan="1">HAPLN1</td><td align="left" rowspan="1" colspan="1">Hyaluronan and proteoglycan link protein 1 stabilizes aggregates of aggrecan and hyaluronan, giving cartilage its tensile strength and elasticity</td><td align="center" rowspan="1" colspan="1">8.951</td><td align="center" rowspan="1" colspan="1">8.142</td></tr><tr><td align="left" rowspan="1" colspan="1">MUC15</td><td align="left" rowspan="1" colspan="1">Mucin 15, cell surface associated</td><td align="center" rowspan="1" colspan="1">8.801</td><td align="center" rowspan="1" colspan="1">7.992</td></tr><tr><td align="left" rowspan="1" colspan="1">HOXB9</td><td align="left" rowspan="1" colspan="1">Homeobox B9</td><td align="center" rowspan="1" colspan="1">8.773</td><td align="center" rowspan="1" colspan="1">7.378</td></tr><tr><td align="left" rowspan="1" colspan="1">MAGEC2</td><td align="left" rowspan="1" colspan="1">Melanoma antigen family C, 2</td><td align="center" rowspan="1" colspan="1">8.693</td><td align="center" rowspan="1" colspan="1">8.884</td></tr><tr><td align="left" rowspan="1" colspan="1">ST6GALNAC5</td><td align="left" rowspan="1" colspan="1">ST6 (alpha-N-acetyl-neuraminyl-2,3-beta-galactosyl-1,3)-N-acetylgalactosaminide alpha-2,6-sialyltransferase 5</td><td align="center" rowspan="1" colspan="1">7.848</td><td align="center" rowspan="1" colspan="1">8.038</td></tr><tr><td align="left" rowspan="1" colspan="1">C11orf41</td><td align="left" rowspan="1" colspan="1">Chromosome 11 open reading frame 41</td><td align="center" rowspan="1" colspan="1">7.781</td><td align="center" rowspan="1" colspan="1">8.141</td></tr><tr><td align="left" rowspan="1" colspan="1">MMP1</td><td align="left" rowspan="1" colspan="1">Matrix metallopeptidase 1 (interstitial collagenase)</td><td align="center" rowspan="1" colspan="1">7.455</td><td align="center" rowspan="1" colspan="1">7.646</td></tr></tbody></table></table-wrap><table-wrap id="tab2d" orientation="portrait" position="anchor"><label>(d)</label><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">Symbol</th><th align="left" rowspan="2" colspan="1">Name</th><th align="center" colspan="2" rowspan="1">log<sub>2</sub>-fold change</th><th align="center" colspan="2" rowspan="1">log<sub>2</sub>-fold change</th></tr><tr><th align="center" colspan="2" rowspan="1">Muscle</th><th align="center" colspan="2" rowspan="1">Bone</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Tumor over bone/muscle</td><td align="left" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">FN1</td><td align="left" rowspan="1" colspan="1">Fibronectin 1</td><td align="center" rowspan="1" colspan="1">7.328</td><td align="center" rowspan="1" colspan="1">6.293</td><td align="center" rowspan="1" colspan="1">6.457</td><td align="center" rowspan="1" colspan="1">19.860</td></tr><tr><td align="left" rowspan="1" colspan="1">COL1A1</td><td align="left" rowspan="1" colspan="1">Collagen, type I, alpha 1</td><td align="center" rowspan="1" colspan="1">6.768</td><td align="center" rowspan="1" colspan="1">3.706</td><td align="center" rowspan="1" colspan="1">5.868</td><td align="center" rowspan="1" colspan="1">11.934</td></tr><tr><td align="left" rowspan="1" colspan="1">CCND1</td><td align="left" rowspan="1" colspan="1">Cyclin D1</td><td align="center" rowspan="1" colspan="1">5.595</td><td align="center" rowspan="1" colspan="1">3.958</td><td align="center" rowspan="1" colspan="1">5.098</td><td align="center" rowspan="1" colspan="1">9.637</td></tr><tr><td align="left" rowspan="1" colspan="1">RGS1</td><td align="left" rowspan="1" colspan="1">Regulator of G-protein signaling 1</td><td align="center" rowspan="1" colspan="1">5.118</td><td align="center" rowspan="1" colspan="1">1.056</td><td align="center" rowspan="1" colspan="1">4.653</td><td align="center" rowspan="1" colspan="1">2.533</td></tr><tr><td align="left" rowspan="1" colspan="1">ITGBL1</td><td align="left" rowspan="1" colspan="1">Integrin, beta-like 1 (with EGF-like repeat domains)</td><td align="center" rowspan="1" colspan="1">5.071</td><td align="center" rowspan="1" colspan="1">3.177</td><td align="center" rowspan="1" colspan="1">3.895</td><td align="center" rowspan="1" colspan="1">12.415</td></tr><tr><td align="left" rowspan="1" colspan="1">COL1A2</td><td align="left" rowspan="1" colspan="1">Collagen, type I, alpha 2</td><td align="center" rowspan="1" colspan="1">4.852</td><td align="center" rowspan="1" colspan="1">8.756</td><td align="center" rowspan="1" colspan="1">4.910</td><td align="center" rowspan="1" colspan="1">14.503</td></tr><tr><td align="left" rowspan="1" colspan="1">MXRA5</td><td align="left" rowspan="1" colspan="1">Matrix-remodelling associated 5</td><td align="center" rowspan="1" colspan="1">4.834</td><td align="center" rowspan="1" colspan="1">1.352</td><td align="center" rowspan="1" colspan="1">4.631</td><td align="center" rowspan="1" colspan="1">2.685</td></tr><tr><td align="left" rowspan="1" colspan="1">POSTN</td><td align="left" rowspan="1" colspan="1">Periostin, osteoblast specific factor</td><td align="center" rowspan="1" colspan="1">4.513</td><td align="center" rowspan="1" colspan="1">5.870</td><td align="center" rowspan="1" colspan="1">7.497</td><td align="center" rowspan="1" colspan="1">1.267</td></tr><tr><td align="left" rowspan="1" colspan="1">PLOD2</td><td align="left" rowspan="1" colspan="1">Procollagen-lysine, 2-oxoglutarate 5-dioxygenase 2</td><td align="center" rowspan="1" colspan="1">4.285</td><td align="center" rowspan="1" colspan="1">1.801</td><td align="center" rowspan="1" colspan="1">4.023</td><td align="center" rowspan="1" colspan="1">3.730</td></tr><tr><td align="left" rowspan="1" colspan="1">COL5A2</td><td align="left" rowspan="1" colspan="1">Collagen, type V, alpha 2</td><td align="center" rowspan="1" colspan="1">4.275</td><td align="center" rowspan="1" colspan="1">1.297</td><td align="center" rowspan="1" colspan="1">4.833</td><td align="center" rowspan="1" colspan="1">1.517</td></tr><tr><td align="left" rowspan="1" colspan="1">COL3A1</td><td align="left" rowspan="1" colspan="1">Collagen, type III, alpha 1</td><td align="center" rowspan="1" colspan="1">4.003</td><td align="center" rowspan="1" colspan="1">13.118</td><td align="center" rowspan="1" colspan="1">5.801</td><td align="center" rowspan="1" colspan="1">6.500</td></tr><tr><td align="left" rowspan="1" colspan="1">SEMA3C</td><td align="left" rowspan="1" colspan="1">Sema domain, immunoglobulin domain (Ig), short basic domain, secreted</td><td align="center" rowspan="1" colspan="1">3.954</td><td align="center" rowspan="1" colspan="1">1.164</td><td align="center" rowspan="1" colspan="1">4.215</td><td align="center" rowspan="1" colspan="1">1.675</td></tr><tr><td align="left" rowspan="1" colspan="1">FBN1</td><td align="left" rowspan="1" colspan="1">Fibrillin 1</td><td align="center" rowspan="1" colspan="1">3.912</td><td align="center" rowspan="1" colspan="1">6.957</td><td align="center" rowspan="1" colspan="1">4.018</td><td align="center" rowspan="1" colspan="1">11.148</td></tr><tr><td align="left" rowspan="1" colspan="1">AEBP1</td><td align="left" rowspan="1" colspan="1">AE binding protein 1</td><td align="center" rowspan="1" colspan="1">3.808</td><td align="center" rowspan="1" colspan="1">3.212</td><td align="center" rowspan="1" colspan="1">4.002</td><td align="center" rowspan="1" colspan="1">4.843</td></tr><tr><td align="left" rowspan="1" colspan="1">SIK1</td><td align="left" rowspan="1" colspan="1">Salt-inducible kinase 1</td><td align="center" rowspan="1" colspan="1">3.805</td><td align="center" rowspan="1" colspan="1">1.219</td><td align="center" rowspan="1" colspan="1">3.566</td><td align="center" rowspan="1" colspan="1">2.484</td></tr><tr><td align="left" rowspan="1" colspan="1">SERPINH1</td><td align="left" rowspan="1" colspan="1">Serpin peptidase inhibitor, clade H (heat shock protein 47), member 1</td><td align="center" rowspan="1" colspan="1">3.706</td><td align="center" rowspan="1" colspan="1">1.652</td><td align="center" rowspan="1" colspan="1">4.145</td><td align="center" rowspan="1" colspan="1">2.098</td></tr><tr><td align="left" rowspan="1" colspan="1">ANTXR1</td><td align="left" rowspan="1" colspan="1">Anthrax toxin receptor 1</td><td align="center" rowspan="1" colspan="1">3.670</td><td align="center" rowspan="1" colspan="1">3.789</td><td align="center" rowspan="1" colspan="1">3.690</td><td align="center" rowspan="1" colspan="1">6.445</td></tr></tbody></table></table-wrap><table-wrap id="tab2e" orientation="portrait" position="anchor"><label>(e)</label><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">Symbol</th><th align="left" rowspan="2" colspan="1">Name</th><th align="center" colspan="2" rowspan="1">log<sub>2</sub>-fold change</th><th align="center" colspan="2" rowspan="1">log<sub>2</sub>-fold change</th></tr><tr><th align="center" colspan="2" rowspan="1">Muscle</th><th align="center" colspan="2" rowspan="1">Bone</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">HELLS</td><td align="left" rowspan="1" colspan="1">Helicase, lymphoid-specific</td><td align="center" rowspan="1" colspan="1">5.315602</td><td align="center" rowspan="1" colspan="1">0.155898</td><td align="center" rowspan="1" colspan="1">&#x02212;0.82713</td><td align="center" rowspan="1" colspan="1">20.2489</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>TNFRSF11A</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>Tumor necrosis factor receptor superfamily, member 11a, and NFKB activator</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>3.017922</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>0.03091</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>1.400993</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>0.202453</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">NFKBID</td><td align="left" rowspan="1" colspan="1">Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, delta</td><td align="center" rowspan="1" colspan="1">2.655352</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">&#x02212;1.47615</td><td align="center" rowspan="1" colspan="1">0.504341</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>TNFRSF25</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>Tumor necrosis factor receptor superfamily, member 25</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>2.432959</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>0.046388</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>0.163954</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>0.490795</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">NFKBIE</td><td align="left" rowspan="1" colspan="1">Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, epsilon</td><td align="center" rowspan="1" colspan="1">2.121015</td><td align="center" rowspan="1" colspan="1">0.062395</td><td align="center" rowspan="1" colspan="1">0.311441</td><td align="center" rowspan="1" colspan="1">0.43382</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>TNF</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>Tumor necrosis factor</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>1.847997</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>0</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>&#x02212;1.42101</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>0.03733</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>TNFRSF10D</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>Tumor necrosis factor receptor superfamily, member 10d, decoy with truncated death domain</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>1.754888</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>0.172968</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>&#x02212;0.1757</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>1.183343</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>TNFRSF1B</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>Tumor necrosis factor receptor superfamily, member 1B</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>1.473438</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>0.709902</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>&#x02212;0.97011</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>6.729401</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>TNFRSF10A</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>Tumor necrosis factor receptor superfamily, member 10a</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>1.411898</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>0.828219</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>0.357701</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>3.004386</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">NFKBIB</td><td align="left" rowspan="1" colspan="1">Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, beta</td><td align="center" rowspan="1" colspan="1">1.193993</td><td align="center" rowspan="1" colspan="1">1.209816</td><td align="center" rowspan="1" colspan="1">0.46055</td><td align="center" rowspan="1" colspan="1">3.484692</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>TNFRSF10B</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>Tumor necrosis factor receptor superfamily, member 10b</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>1.094157</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>1.908597</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>0.425446</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>5.242006</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>TNFRSF21</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>Tumor necrosis factor receptor superfamily, member 21</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>1.055762</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>3.882038</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>0.745815</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>8.305711</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>TNFRSF1A</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>Tumor necrosis factor receptor superfamily, member 1A</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>0.875167</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>3.790938</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>&#x02212;0.11707</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>13.0344</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">NFKBIZ</td><td align="left" rowspan="1" colspan="1">Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, zeta</td><td align="center" rowspan="1" colspan="1">0.575974</td><td align="center" rowspan="1" colspan="1">3.698951</td><td align="center" rowspan="1" colspan="1">0.344657</td><td align="center" rowspan="1" colspan="1">7.493136</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>RIPK1</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>Receptor (TNFRSF)-interacting serine-threonine kinase 1</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>0.494467</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>3.11749</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>&#x02212;1.08854</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>16.1392</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">NKRF</td><td align="left" rowspan="1" colspan="1">NFKB repressing factor</td><td align="center" rowspan="1" colspan="1">0.475722</td><td align="center" rowspan="1" colspan="1">2.156087</td><td align="center" rowspan="1" colspan="1">&#x02212;0.86397</td><td align="center" rowspan="1" colspan="1">9.434166</td></tr><tr><td align="left" rowspan="1" colspan="1">NFKB1</td><td align="left" rowspan="1" colspan="1">Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1</td><td align="center" rowspan="1" colspan="1">0.432959</td><td align="center" rowspan="1" colspan="1">2.054532</td><td align="center" rowspan="1" colspan="1">&#x02212;0.65865</td><td align="center" rowspan="1" colspan="1">7.568586</td></tr><tr><td align="left" rowspan="1" colspan="1">CHUK</td><td align="left" rowspan="1" colspan="1">Conserved helix-loop-helix ubiquitous kinase</td><td align="center" rowspan="1" colspan="1">0.176126</td><td align="center" rowspan="1" colspan="1">2.961281</td><td align="center" rowspan="1" colspan="1">&#x02212;1.20204</td><td align="center" rowspan="1" colspan="1">13.30333</td></tr><tr><td align="left" rowspan="1" colspan="1">RELA</td><td align="left" rowspan="1" colspan="1">V-rel reticuloendotheliosis viral oncogene homolog A (avian)</td><td align="center" rowspan="1" colspan="1">0.013848</td><td align="center" rowspan="1" colspan="1">1.263837</td><td align="center" rowspan="1" colspan="1">0.287167</td><td align="center" rowspan="1" colspan="1">1.803044</td></tr><tr><td align="left" rowspan="1" colspan="1">NFKB2</td><td align="left" rowspan="1" colspan="1">Nuclear factor of kappa light polypeptide gene enhancer in B-cells 2 (p49/p100)</td><td align="center" rowspan="1" colspan="1">&#x02212;0.08641</td><td align="center" rowspan="1" colspan="1">0.312993</td><td align="center" rowspan="1" colspan="1">0.485882</td><td align="center" rowspan="1" colspan="1">0.360442</td></tr><tr><td align="left" rowspan="1" colspan="1">NKAPP1</td><td align="left" rowspan="1" colspan="1">NFKB activating protein pseudogene 1</td><td align="center" rowspan="1" colspan="1">&#x02212;0.10692</td><td align="center" rowspan="1" colspan="1">0.825177</td><td align="center" rowspan="1" colspan="1">&#x02212;0.99449</td><td align="center" rowspan="1" colspan="1">2.655392</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>TNFRSF10C</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>Tumor necrosis factor receptor superfamily, member 10c, decoy without an intracellular domain</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>&#x02212;0.152</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>0.064676</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>&#x02212;5.56891</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>6.321515</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">NKIRAS2</td><td align="left" rowspan="1" colspan="1">NFKB inhibitor interacting Ras-like 2</td><td align="center" rowspan="1" colspan="1">&#x02212;0.60768</td><td align="center" rowspan="1" colspan="1">1.095135</td><td align="center" rowspan="1" colspan="1">&#x02212;0.88758</td><td align="center" rowspan="1" colspan="1">2.299946</td></tr><tr><td align="left" rowspan="1" colspan="1">NFKBIL1</td><td align="left" rowspan="1" colspan="1">Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor-like 1</td><td align="center" rowspan="1" colspan="1">&#x02212;0.8719</td><td align="center" rowspan="1" colspan="1">0.141933</td><td align="center" rowspan="1" colspan="1">&#x02212;0.08357</td><td align="center" rowspan="1" colspan="1">0.140418</td></tr><tr><td align="left" rowspan="1" colspan="1">NKIRAS1</td><td align="left" rowspan="1" colspan="1">NFKB inhibitor interacting Ras-like 1</td><td align="center" rowspan="1" colspan="1">&#x02212;0.87428</td><td align="center" rowspan="1" colspan="1">6.296399</td><td align="center" rowspan="1" colspan="1">1.467735</td><td align="center" rowspan="1" colspan="1">2.122983</td></tr><tr><td align="left" rowspan="1" colspan="1">TANK</td><td align="left" rowspan="1" colspan="1">TRAF family member-associated NFKB activator</td><td align="center" rowspan="1" colspan="1">&#x02212;0.983</td><td align="center" rowspan="1" colspan="1">6.777124</td><td align="center" rowspan="1" colspan="1">&#x02212;1.51908</td><td align="center" rowspan="1" colspan="1">16.95872</td></tr><tr><td align="left" rowspan="1" colspan="1">NKAP</td><td align="left" rowspan="1" colspan="1">NFKB activating protein</td><td align="center" rowspan="1" colspan="1">&#x02212;1.35735</td><td align="center" rowspan="1" colspan="1">14.22458</td><td align="center" rowspan="1" colspan="1">&#x02212;0.78243</td><td align="center" rowspan="1" colspan="1">16.46287</td></tr><tr><td align="left" rowspan="1" colspan="1">NFKBIA</td><td align="left" rowspan="1" colspan="1">Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha</td><td align="center" rowspan="1" colspan="1">&#x02212;1.85483</td><td align="center" rowspan="1" colspan="1">40.32743</td><td align="center" rowspan="1" colspan="1">&#x02212;0.31802</td><td align="center" rowspan="1" colspan="1">23.95275</td></tr><tr><td align="left" rowspan="1" colspan="1">NKAPL</td><td align="left" rowspan="1" colspan="1">NFKB activating protein-like</td><td align="center" rowspan="1" colspan="1">&#x02212;5.57347</td><td align="center" rowspan="1" colspan="1">5.875743</td><td align="center" rowspan="1" colspan="1">&#x02212;1.40215</td><td align="center" rowspan="1" colspan="1">0.534643</td></tr></tbody></table></table-wrap></table-wrap-group><table-wrap-group id="tab3" orientation="portrait" position="float"><label>Table 3</label><caption><p>Deregulation of genes for drug disposition. Analysis of RNASeq for at least twofold overexpression (italic font) or underexpression (bold font) of genes for (a) transport and (b) metabolism in tumor compared to muscle and bone. For the export transporters (ABC transporters), only overexpression is considered relevant for drug resistance. Not shown in the table are the underexpressed genes (ABCA7, ABCA8, ABCA13, ABCB6, ABCB10, ABCC6, ABCC6P1, ABCC6P2, ABCC8, ABCC11, ABCD2, ABCG2, and ABCG5).</p></caption><table-wrap id="tab3a" orientation="portrait" position="anchor"><caption><p>(a) Transport</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">Gene ID </th><th align="center" rowspan="2" colspan="1">Symbol</th><th align="left" rowspan="2" colspan="1">Name</th><th align="center" rowspan="1" colspan="1">Tumor bone</th><th align="center" rowspan="1" colspan="1">Tumor muscle</th></tr><tr><th align="center" rowspan="1" colspan="1">log<sub>2</sub>-fold change</th><th align="center" rowspan="1" colspan="1">log<sub>2</sub>-fold change</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">650655</td><td align="center" rowspan="1" colspan="1">ABCA17P</td><td align="left" rowspan="1" colspan="1">ATP-binding cassette, subfamily A (ABC1), member 17, pseudogene</td><td align="center" rowspan="1" colspan="1">&#x02212;1.360</td><td align="center" rowspan="1" colspan="1">&#x02212;<italic>2.116 </italic></td></tr><tr><td align="left" rowspan="1" colspan="1">24</td><td align="center" rowspan="1" colspan="1">ABCA4</td><td align="left" rowspan="1" colspan="1">ATP-binding cassette, subfamily A (ABC1), member 4</td><td align="center" rowspan="1" colspan="1">&#x02212;<italic>2.038 </italic></td><td align="center" rowspan="1" colspan="1">&#x02212;<italic>2.802 </italic></td></tr><tr><td align="center" colspan="5" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="1" colspan="1">6555</td><td align="center" rowspan="1" colspan="1">SLC10A2</td><td align="left" rowspan="1" colspan="1">Solute carrier family 10 (sodium/bile acid cotransporter family), member 2</td><td align="center" rowspan="1" colspan="1">&#x02212;1.962</td><td align="center" rowspan="1" colspan="1">
<bold>&#x02212;2.112</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">345274</td><td align="center" rowspan="1" colspan="1">SLC10A6</td><td align="left" rowspan="1" colspan="1">Solute carrier family 10 (sodium/bile acid cotransporter family), member 6</td><td align="center" rowspan="1" colspan="1">&#x02212;<italic>2.623 </italic></td><td align="center" rowspan="1" colspan="1">&#x02212;<italic>3.240 </italic></td></tr><tr><td align="left" rowspan="1" colspan="1">6563</td><td align="center" rowspan="1" colspan="1">SLC14A1</td><td align="left" rowspan="1" colspan="1">Solute carrier family 14 (urea transporter), member 1 (Kidd blood group)</td><td align="center" rowspan="1" colspan="1">
<bold>&#x02212;3.074</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>&#x02212;3.152</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">6565</td><td align="center" rowspan="1" colspan="1">SLC15A2</td><td align="left" rowspan="1" colspan="1">Solute carrier family 15 (H+/peptide transporter), member 2</td><td align="center" rowspan="1" colspan="1">
<bold>&#x02212;2.027</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>&#x02212;2.152</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">6566</td><td align="center" rowspan="1" colspan="1">SLC16A1</td><td align="left" rowspan="1" colspan="1">Solute carrier family 16, member 1 (monocarboxylic acid transporter 1)</td><td align="center" rowspan="1" colspan="1">&#x02212;1.401</td><td align="center" rowspan="1" colspan="1">&#x02212;<italic>2.170 </italic></td></tr><tr><td align="left" rowspan="1" colspan="1">117247</td><td align="center" rowspan="1" colspan="1">SLC16A10</td><td align="left" rowspan="1" colspan="1">Solute carrier family 16, member 10 (aromatic amino acid transporter)</td><td align="center" rowspan="1" colspan="1">&#x02212;<italic>2.113 </italic></td><td align="center" rowspan="1" colspan="1">&#x02212;<italic>2.848 </italic></td></tr><tr><td align="left" rowspan="1" colspan="1">6567</td><td align="center" rowspan="1" colspan="1">SLC16A2</td><td align="left" rowspan="1" colspan="1">Solute carrier family 16, member 2 (monocarboxylic acid transporter 8)</td><td align="center" rowspan="1" colspan="1">&#x02212;<italic>3.242 </italic></td><td align="center" rowspan="1" colspan="1">&#x02212;<italic>3.848 </italic></td></tr><tr><td align="left" rowspan="1" colspan="1">10786</td><td align="center" rowspan="1" colspan="1">SLC17A3</td><td align="left" rowspan="1" colspan="1">Solute carrier family 17 (sodium phosphate), member 3</td><td align="center" rowspan="1" colspan="1">
<bold>&#x02212;2.868</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>&#x02212;2.959</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">6571</td><td align="center" rowspan="1" colspan="1">SLC18A2</td><td align="left" rowspan="1" colspan="1">Solute carrier family 18 (vesicular monoamine), member 2</td><td align="center" rowspan="1" colspan="1">
<bold>&#x02212;2.087</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>&#x02212;2.194</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">6573</td><td align="center" rowspan="1" colspan="1">SLC19A1</td><td align="left" rowspan="1" colspan="1">Solute carrier family 19 (folate transporter), member 1</td><td align="center" rowspan="1" colspan="1">
<bold>&#x02212;2.099</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>&#x02212;2.203</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">10560</td><td align="center" rowspan="1" colspan="1">SLC19A2</td><td align="left" rowspan="1" colspan="1">Solute carrier family 19 (thiamine transporter), member 2</td><td align="center" rowspan="1" colspan="1">&#x02212;1.820</td><td align="center" rowspan="1" colspan="1">&#x02212;<italic>2.548 </italic></td></tr><tr><td align="left" rowspan="1" colspan="1">80704</td><td align="center" rowspan="1" colspan="1">SLC19A3</td><td align="left" rowspan="1" colspan="1">Solute carrier family 19, member 3</td><td align="center" rowspan="1" colspan="1">
<bold>&#x02212;3.331</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>&#x02212;3.478</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">387775</td><td align="center" rowspan="1" colspan="1">SLC22A10</td><td align="left" rowspan="1" colspan="1">Solute carrier family 22, member 10</td><td align="center" rowspan="1" colspan="1">&#x02212;<italic>5.711 </italic></td><td align="center" rowspan="1" colspan="1">&#x02212;<italic>6.085 </italic></td></tr><tr><td align="left" rowspan="1" colspan="1">9390</td><td align="center" rowspan="1" colspan="1">SLC22A13</td><td align="left" rowspan="1" colspan="1">Solute carrier family 22 (organic anion transporter), member 13</td><td align="center" rowspan="1" colspan="1">&#x02212;<italic>2.623 </italic></td><td align="center" rowspan="1" colspan="1">&#x02212;<italic>3.217 </italic></td></tr><tr><td align="left" rowspan="1" colspan="1">85413</td><td align="center" rowspan="1" colspan="1">SLC22A16</td><td align="left" rowspan="1" colspan="1">Solute carrier family 22 (organic cation/carnitine transporter), member 16</td><td align="center" rowspan="1" colspan="1">
<bold>&#x02212;8.101</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>&#x02212;7.299</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">51310</td><td align="center" rowspan="1" colspan="1">SLC22A17</td><td align="left" rowspan="1" colspan="1">Solute carrier family 22, member 17</td><td align="center" rowspan="1" colspan="1">&#x02212;1.475</td><td align="center" rowspan="1" colspan="1">&#x02212;<italic>2.175 </italic></td></tr><tr><td align="left" rowspan="1" colspan="1">5002</td><td align="center" rowspan="1" colspan="1">SLC22A18</td><td align="left" rowspan="1" colspan="1">Solute carrier family 22, member 18</td><td align="center" rowspan="1" colspan="1">&#x02212;<italic>2.038 </italic></td><td align="center" rowspan="1" colspan="1">&#x02212;<italic>2.722 </italic></td></tr><tr><td align="left" rowspan="1" colspan="1">6582</td><td align="center" rowspan="1" colspan="1">SLC22A2</td><td align="left" rowspan="1" colspan="1">Solute carrier family 22 (organic cation transporter), member 2</td><td align="center" rowspan="1" colspan="1">&#x02212;<italic>4.793 </italic></td><td align="center" rowspan="1" colspan="1">&#x02212;<italic>5.216 </italic></td></tr><tr><td align="left" rowspan="1" colspan="1">6581</td><td align="center" rowspan="1" colspan="1">SLC22A3</td><td align="left" rowspan="1" colspan="1">Solute carrier family 22 (extraneuronal monoamine transporter), member 3</td><td align="center" rowspan="1" colspan="1">&#x02212;<italic>2.554 </italic></td><td align="center" rowspan="1" colspan="1">&#x02212;<italic>3.182 </italic></td></tr><tr><td align="left" rowspan="1" colspan="1">6583</td><td align="center" rowspan="1" colspan="1">SLC22A4</td><td align="left" rowspan="1" colspan="1">Solute carrier family 22 (organic cation/ergothioneine transporter), member 4</td><td align="center" rowspan="1" colspan="1">
<bold>&#x02212;3.603</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>&#x02212;3.776</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">151295</td><td align="center" rowspan="1" colspan="1">SLC23A3</td><td align="left" rowspan="1" colspan="1">Solute carrier family 23 (nucleobase transporters), member 3</td><td align="center" rowspan="1" colspan="1">&#x02212;<italic>2.109 </italic></td><td align="center" rowspan="1" colspan="1">&#x02212;<italic>2.848 </italic></td></tr><tr><td align="left" rowspan="1" colspan="1">10478</td><td align="center" rowspan="1" colspan="1">SLC25A17</td><td align="left" rowspan="1" colspan="1">Solute carrier family 25 (mitochondrial carrier), member 17</td><td align="center" rowspan="1" colspan="1">&#x02212;1.311</td><td align="center" rowspan="1" colspan="1">&#x02212;<italic>2.077 </italic></td></tr><tr><td align="left" rowspan="1" colspan="1">83733</td><td align="center" rowspan="1" colspan="1">SLC25A18</td><td align="left" rowspan="1" colspan="1">Solute carrier family 25 (mitochondrial carrier), member 18</td><td align="center" rowspan="1" colspan="1">&#x02212;1.846</td><td align="center" rowspan="1" colspan="1">&#x02212;<italic>2.570 </italic></td></tr><tr><td align="left" rowspan="1" colspan="1">788</td><td align="center" rowspan="1" colspan="1">SLC25A20</td><td align="left" rowspan="1" colspan="1">Solute carrier family 25 (carnitine/acylcarnitine translocase), member 20</td><td align="center" rowspan="1" colspan="1">
<bold>&#x02212;2.105</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>&#x02212;2.207</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">89874</td><td align="center" rowspan="1" colspan="1">SLC25A21</td><td align="left" rowspan="1" colspan="1">Solute carrier family 25 (mitochondrial oxodicarboxylate carrier), member 21</td><td align="center" rowspan="1" colspan="1">
<bold>&#x02212;2.962</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>&#x02212;3.105</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">51312</td><td align="center" rowspan="1" colspan="1">SLC25A37</td><td align="left" rowspan="1" colspan="1">Solute carrier family 25, member 37</td><td align="center" rowspan="1" colspan="1">
<bold>&#x02212;4.633</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>&#x02212;4.866</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">51629</td><td align="center" rowspan="1" colspan="1">SLC25A39</td><td align="left" rowspan="1" colspan="1">Solute carrier family 25, member 39</td><td align="center" rowspan="1" colspan="1">
<bold>&#x02212;2.585</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>&#x02212;2.737</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">203427</td><td align="center" rowspan="1" colspan="1">SLC25A43</td><td align="left" rowspan="1" colspan="1">Solute carrier family 25, member 43</td><td align="center" rowspan="1" colspan="1">&#x02212;1.325</td><td align="center" rowspan="1" colspan="1">&#x02212;<italic>2.088 </italic></td></tr><tr><td align="left" rowspan="1" colspan="1">65012</td><td align="center" rowspan="1" colspan="1">SLC26A10</td><td align="left" rowspan="1" colspan="1">Solute carrier family 26, member 10</td><td align="center" rowspan="1" colspan="1">&#x02212;<italic>3.896 </italic></td><td align="center" rowspan="1" colspan="1">&#x02212;<italic>4.472 </italic></td></tr><tr><td align="left" rowspan="1" colspan="1">115111</td><td align="center" rowspan="1" colspan="1">SLC26A7</td><td align="left" rowspan="1" colspan="1">Solute carrier family 26, member 7</td><td align="center" rowspan="1" colspan="1">&#x02212;<italic>3.431 </italic></td><td align="center" rowspan="1" colspan="1">&#x02212;<italic>4.018 </italic></td></tr><tr><td align="left" rowspan="1" colspan="1">116369</td><td align="center" rowspan="1" colspan="1">SLC26A8</td><td align="left" rowspan="1" colspan="1">Solute carrier family 26, member 8</td><td align="center" rowspan="1" colspan="1">
<bold>&#x02212;5.354</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>&#x02212;5.536</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">115019</td><td align="center" rowspan="1" colspan="1">SLC26A9</td><td align="left" rowspan="1" colspan="1">Solute carrier family 26, member 9</td><td align="center" rowspan="1" colspan="1">&#x02212;1.623</td><td align="center" rowspan="1" colspan="1">&#x02212;<italic>2.419 </italic></td></tr><tr><td align="left" rowspan="1" colspan="1">11001</td><td align="center" rowspan="1" colspan="1">SLC27A2</td><td align="left" rowspan="1" colspan="1">Solute carrier family 27 (fatty acid transporter), member 2</td><td align="center" rowspan="1" colspan="1">
<bold>&#x02212;4.278</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>&#x02212;4.487</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">64078</td><td align="center" rowspan="1" colspan="1">SLC28A3</td><td align="left" rowspan="1" colspan="1">Solute carrier family 28 (sodium-coupled nucleoside transporter), member 3</td><td align="center" rowspan="1" colspan="1">
<bold>&#x02212;4.543</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>&#x02212;4.812</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">222962</td><td align="center" rowspan="1" colspan="1">SLC29A4</td><td align="left" rowspan="1" colspan="1">Solute carrier family 29 (nucleoside transporters), member 4</td><td align="center" rowspan="1" colspan="1">&#x02212;1.962</td><td align="center" rowspan="1" colspan="1">
<bold>&#x02212;2.045</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">81031</td><td align="center" rowspan="1" colspan="1">SLC2A10</td><td align="left" rowspan="1" colspan="1">Solute carrier family 2 (facilitated glucose transporter), member 10</td><td align="center" rowspan="1" colspan="1">&#x02212;<italic>2.532 </italic></td><td align="center" rowspan="1" colspan="1">&#x02212;<italic>3.170 </italic></td></tr><tr><td align="left" rowspan="1" colspan="1">6518</td><td align="center" rowspan="1" colspan="1">SLC2A5</td><td align="left" rowspan="1" colspan="1">Solute carrier family 2 (facilitated glucose/fructose transporter), member 5</td><td align="center" rowspan="1" colspan="1">
<bold>&#x02212;3.647</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>&#x02212;3.821</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">55532</td><td align="center" rowspan="1" colspan="1">SLC30A10</td><td align="left" rowspan="1" colspan="1">Solute carrier family 30, member 10</td><td align="center" rowspan="1" colspan="1">
<bold>&#x02212;3.547</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>&#x02212;3.725</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">7782</td><td align="center" rowspan="1" colspan="1">SLC30A4</td><td align="left" rowspan="1" colspan="1">Solute carrier family 30 (zinc transporter), member 4</td><td align="center" rowspan="1" colspan="1">&#x02212;<italic>2.832 </italic></td><td align="center" rowspan="1" colspan="1">&#x02212;<italic>3.372 </italic></td></tr><tr><td align="left" rowspan="1" colspan="1">6569</td><td align="center" rowspan="1" colspan="1">SLC34A1</td><td align="left" rowspan="1" colspan="1">Solute carrier family 34 (sodium phosphate), member 1</td><td align="center" rowspan="1" colspan="1">
<bold>&#x02212;4.716</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>&#x02212;4.941</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">340146</td><td align="center" rowspan="1" colspan="1">SLC35D3</td><td align="left" rowspan="1" colspan="1">Solute carrier family 35, member D3</td><td align="center" rowspan="1" colspan="1">
<bold>&#x02212;5.662</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>&#x02212;5.906</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">54733</td><td align="center" rowspan="1" colspan="1">SLC35F2</td><td align="left" rowspan="1" colspan="1">Solute carrier family 35, member F2</td><td align="center" rowspan="1" colspan="1">&#x02212;1.433</td><td align="center" rowspan="1" colspan="1">&#x02212;<italic>2.170 </italic></td></tr><tr><td align="left" rowspan="1" colspan="1">206358</td><td align="center" rowspan="1" colspan="1">SLC36A1</td><td align="left" rowspan="1" colspan="1">Solute carrier family 36 (proton/amino acid symporter), member 1</td><td align="center" rowspan="1" colspan="1">
<bold>&#x02212;2.265</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>&#x02212;2.345</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">285641</td><td align="center" rowspan="1" colspan="1">SLC36A3</td><td align="left" rowspan="1" colspan="1">Solute carrier family 36 (proton/amino acid symporter), member 3</td><td align="center" rowspan="1" colspan="1">
<bold>&#x02212;2.284</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>&#x02212;2.393</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">54020</td><td align="center" rowspan="1" colspan="1">SLC37A1</td><td align="left" rowspan="1" colspan="1">Solute carrier family 37 (glycerol-3-phosphate transporter), member 1</td><td align="center" rowspan="1" colspan="1">
<bold>&#x02212;2.112</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>&#x02212;2.212</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">2542</td><td align="center" rowspan="1" colspan="1">SLC37A4</td><td align="left" rowspan="1" colspan="1">Solute carrier family 37 (glucose-6-phosphate transporter), member 4</td><td align="center" rowspan="1" colspan="1">
<bold>&#x02212;2.117</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>&#x02212;2.219</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">151258</td><td align="center" rowspan="1" colspan="1">SLC38A11</td><td align="left" rowspan="1" colspan="1">Solute carrier family 38, member 11</td><td align="center" rowspan="1" colspan="1">&#x02212;<italic>2.410 </italic></td><td align="center" rowspan="1" colspan="1">&#x02212;<italic>3.085 </italic></td></tr><tr><td align="left" rowspan="1" colspan="1">55089</td><td align="center" rowspan="1" colspan="1">SLC38A4</td><td align="left" rowspan="1" colspan="1">Solute carrier family 38, member 4</td><td align="center" rowspan="1" colspan="1">&#x02212;1.837</td><td align="center" rowspan="1" colspan="1">&#x02212;<italic>2.548 </italic></td></tr><tr><td align="left" rowspan="1" colspan="1">92745</td><td align="center" rowspan="1" colspan="1">SLC38A5</td><td align="left" rowspan="1" colspan="1">Solute carrier family 38, member 5</td><td align="center" rowspan="1" colspan="1">&#x02212;1.994</td><td align="center" rowspan="1" colspan="1">
<bold>&#x02212;2.152</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">91252</td><td align="center" rowspan="1" colspan="1">SLC39A13</td><td align="left" rowspan="1" colspan="1">Solute carrier family 39 (zinc transporter), member 13</td><td align="center" rowspan="1" colspan="1">&#x02212;1.301</td><td align="center" rowspan="1" colspan="1">&#x02212;<italic>2.070 </italic></td></tr><tr><td align="left" rowspan="1" colspan="1">23516</td><td align="center" rowspan="1" colspan="1">SLC39A14</td><td align="left" rowspan="1" colspan="1">Solute carrier family 39 (zinc transporter), member 14</td><td align="center" rowspan="1" colspan="1">&#x02212;<italic>2.569 </italic></td><td align="center" rowspan="1" colspan="1">&#x02212;<italic>3.188 </italic></td></tr><tr><td align="left" rowspan="1" colspan="1">29985</td><td align="center" rowspan="1" colspan="1">SLC39A3</td><td align="left" rowspan="1" colspan="1">Solute carrier family 39 (zinc transporter), member 3</td><td align="center" rowspan="1" colspan="1">
<bold>&#x02212;2.032</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>&#x02212;2.152</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">283375</td><td align="center" rowspan="1" colspan="1">SLC39A5</td><td align="left" rowspan="1" colspan="1">Solute carrier family 39 (metal ion transporter), member 5</td><td align="center" rowspan="1" colspan="1">&#x02212;1.623</td><td align="center" rowspan="1" colspan="1">&#x02212;<italic>2.370 </italic></td></tr><tr><td align="left" rowspan="1" colspan="1">7922</td><td align="center" rowspan="1" colspan="1">SLC39A7</td><td align="left" rowspan="1" colspan="1">Solute carrier family 39 (zinc transporter), member 7</td><td align="center" rowspan="1" colspan="1">&#x02212;1.273</td><td align="center" rowspan="1" colspan="1">&#x02212;<italic>2.058 </italic></td></tr><tr><td align="left" rowspan="1" colspan="1">30061</td><td align="center" rowspan="1" colspan="1">SLC40A1</td><td align="left" rowspan="1" colspan="1">Solute carrier family 40 (iron-regulated transporter), member 1</td><td align="center" rowspan="1" colspan="1">
<bold>&#x02212;3.612</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>&#x02212;3.796</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">84102</td><td align="center" rowspan="1" colspan="1">SLC41A2</td><td align="left" rowspan="1" colspan="1">Solute carrier family 41, member 2</td><td align="center" rowspan="1" colspan="1">&#x02212;1.293</td><td align="center" rowspan="1" colspan="1">&#x02212;<italic>2.070 </italic></td></tr><tr><td align="left" rowspan="1" colspan="1">8501</td><td align="center" rowspan="1" colspan="1">SLC43A1</td><td align="left" rowspan="1" colspan="1">Solute carrier family 43, member 1</td><td align="center" rowspan="1" colspan="1">
<bold>&#x02212;2.013</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>&#x02212;2.152</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">57153</td><td align="center" rowspan="1" colspan="1">SLC44A2</td><td align="left" rowspan="1" colspan="1">Solute carrier family 44, member 2</td><td align="center" rowspan="1" colspan="1">
<bold>&#x02212;2.047</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>&#x02212;2.152</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">50651</td><td align="center" rowspan="1" colspan="1">SLC45A1</td><td align="left" rowspan="1" colspan="1">Solute carrier family 45, member 1</td><td align="center" rowspan="1" colspan="1">&#x02212;<italic>2.038 </italic></td><td align="center" rowspan="1" colspan="1">&#x02212;<italic>2.722 </italic></td></tr><tr><td align="left" rowspan="1" colspan="1">146802</td><td align="center" rowspan="1" colspan="1">SLC47A2</td><td align="left" rowspan="1" colspan="1">Solute carrier family 47, member 2</td><td align="center" rowspan="1" colspan="1">&#x02212;1.962</td><td align="center" rowspan="1" colspan="1">
<bold>&#x02212;2.026</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">6521</td><td align="center" rowspan="1" colspan="1">SLC4A1</td><td align="left" rowspan="1" colspan="1">Solute carrier family 4, anion exchanger, member 1</td><td align="center" rowspan="1" colspan="1">
<bold>&#x02212;6.513</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>&#x02212;6.453</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">57282</td><td align="center" rowspan="1" colspan="1">SLC4A10</td><td align="left" rowspan="1" colspan="1">Solute carrier family 4, sodium bicarbonate transporter, member 10</td><td align="center" rowspan="1" colspan="1">
<bold>&#x02212;2.640</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>&#x02212;2.753</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">83959</td><td align="center" rowspan="1" colspan="1">SLC4A11</td><td align="left" rowspan="1" colspan="1">Solute carrier family 4, sodium borate transporter, member 11</td><td align="center" rowspan="1" colspan="1">&#x02212;1.846</td><td align="center" rowspan="1" colspan="1">&#x02212;<italic>2.569 </italic></td></tr><tr><td align="left" rowspan="1" colspan="1">6508</td><td align="center" rowspan="1" colspan="1">SLC4A3</td><td align="left" rowspan="1" colspan="1">Solute carrier family 4, anion exchanger, member 3</td><td align="center" rowspan="1" colspan="1">&#x02212;1.261</td><td align="center" rowspan="1" colspan="1">&#x02212;<italic>2.045 </italic></td></tr><tr><td align="left" rowspan="1" colspan="1">8671</td><td align="center" rowspan="1" colspan="1">SLC4A4</td><td align="left" rowspan="1" colspan="1">Solute carrier family 4, sodium bicarbonate cotransporter, member 4</td><td align="center" rowspan="1" colspan="1">&#x02212;<italic>2.445 </italic></td><td align="center" rowspan="1" colspan="1">&#x02212;<italic>3.113 </italic></td></tr><tr><td align="left" rowspan="1" colspan="1">9497</td><td align="center" rowspan="1" colspan="1">SLC4A7</td><td align="left" rowspan="1" colspan="1">Solute carrier family 4, sodium bicarbonate cotransporter, member 7</td><td align="center" rowspan="1" colspan="1">&#x02212;<italic>2.717 </italic></td><td align="center" rowspan="1" colspan="1">&#x02212;<italic>3.307 </italic></td></tr><tr><td align="left" rowspan="1" colspan="1">6523</td><td align="center" rowspan="1" colspan="1">SLC5A1</td><td align="left" rowspan="1" colspan="1">Solute carrier family 5 (sodium/glucose cotransporter), member 1</td><td align="center" rowspan="1" colspan="1">
<bold>&#x02212;2.547</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>&#x02212;2.705</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">159963</td><td align="center" rowspan="1" colspan="1">SLC5A12</td><td align="left" rowspan="1" colspan="1">Solute carrier family 5 (sodium/glucose cotransporter), member 12</td><td align="center" rowspan="1" colspan="1">&#x02212;<italic>4.753 </italic></td><td align="center" rowspan="1" colspan="1">&#x02212;<italic>5.206 </italic></td></tr><tr><td align="left" rowspan="1" colspan="1">6527</td><td align="center" rowspan="1" colspan="1">SLC5A4</td><td align="left" rowspan="1" colspan="1">Solute carrier family 5 (low affinity glucose cotransporter), member 4</td><td align="center" rowspan="1" colspan="1">
<bold>&#x02212;3.969</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>&#x02212;4.249</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">6540</td><td align="center" rowspan="1" colspan="1">SLC6A13</td><td align="left" rowspan="1" colspan="1">Solute carrier family 6 (neurotransmitter transporter, GABA), member 13</td><td align="center" rowspan="1" colspan="1">&#x02212;1.328</td><td align="center" rowspan="1" colspan="1">&#x02212;<italic>2.092 </italic></td></tr><tr><td align="left" rowspan="1" colspan="1">55117</td><td align="center" rowspan="1" colspan="1">SLC6A15</td><td align="left" rowspan="1" colspan="1">Solute carrier family 6 (neutral amino acid transporter), member 15</td><td align="center" rowspan="1" colspan="1">&#x02212;1.623</td><td align="center" rowspan="1" colspan="1">&#x02212;<italic>2.333 </italic></td></tr><tr><td align="left" rowspan="1" colspan="1">388662</td><td align="center" rowspan="1" colspan="1">SLC6A17</td><td align="left" rowspan="1" colspan="1">Solute carrier family 6, member 17</td><td align="center" rowspan="1" colspan="1">&#x02212;<italic>2.038 </italic></td><td align="center" rowspan="1" colspan="1">&#x02212;<italic>2.728 </italic></td></tr><tr><td align="left" rowspan="1" colspan="1">54716</td><td align="center" rowspan="1" colspan="1">SLC6A20</td><td align="left" rowspan="1" colspan="1">Solute carrier family 6 (proline IMINO transporter), member 20</td><td align="center" rowspan="1" colspan="1">&#x02212;1.697</td><td align="center" rowspan="1" colspan="1">&#x02212;<italic>2.433 </italic></td></tr><tr><td align="left" rowspan="1" colspan="1">6532</td><td align="center" rowspan="1" colspan="1">SLC6A4</td><td align="left" rowspan="1" colspan="1">Solute carrier family 6 (neurotransmitter transporter, serotonin), member 4</td><td align="center" rowspan="1" colspan="1">
<bold>&#x02212;2.512</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>&#x02212;2.611</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">6534</td><td align="center" rowspan="1" colspan="1">SLC6A7</td><td align="left" rowspan="1" colspan="1">Solute carrier family 6 (neurotransmitter transporter, L-proline), member 7</td><td align="center" rowspan="1" colspan="1">&#x02212;<italic>2.623 </italic></td><td align="center" rowspan="1" colspan="1">&#x02212;<italic>3.228 </italic></td></tr><tr><td align="left" rowspan="1" colspan="1">56301</td><td align="center" rowspan="1" colspan="1">SLC7A10</td><td align="left" rowspan="1" colspan="1">Solute carrier family 7, (neutral amino acid transporter, y+ system) member 10</td><td align="center" rowspan="1" colspan="1">
<bold>&#x02212;3.421</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>&#x02212;3.603</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">6547</td><td align="center" rowspan="1" colspan="1">SLC8A3</td><td align="left" rowspan="1" colspan="1">Solute carrier family 8 (sodium/calcium exchanger), member 3</td><td align="center" rowspan="1" colspan="1">
<bold>&#x02212;2.204</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>&#x02212;2.309</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">285335</td><td align="center" rowspan="1" colspan="1">SLC9A10</td><td align="left" rowspan="1" colspan="1">Solute carrier family 9, member 10</td><td align="center" rowspan="1" colspan="1">&#x02212;1.208</td><td align="center" rowspan="1" colspan="1">&#x02212;<italic>2.000 </italic></td></tr><tr><td align="left" rowspan="1" colspan="1">6549</td><td align="center" rowspan="1" colspan="1">SLC9A2</td><td align="left" rowspan="1" colspan="1">Solute carrier family 9 (sodium/hydrogen exchanger), member 2</td><td align="center" rowspan="1" colspan="1">&#x02212;<italic>2.038 </italic></td><td align="center" rowspan="1" colspan="1">&#x02212;<italic>2.706 </italic></td></tr><tr><td align="left" rowspan="1" colspan="1">9368</td><td align="center" rowspan="1" colspan="1">SLC9A3R1</td><td align="left" rowspan="1" colspan="1">Solute carrier family 9 (sodium/hydrogen exchanger), member 3 regulator 1</td><td align="center" rowspan="1" colspan="1">
<bold>&#x02212;2.760</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>&#x02212;2.846</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">9351</td><td align="center" rowspan="1" colspan="1">SLC9A3R2</td><td align="left" rowspan="1" colspan="1">Solute carrier family 9 (sodium/hydrogen exchanger), member 3 regulator 2</td><td align="center" rowspan="1" colspan="1">&#x02212;1.889</td><td align="center" rowspan="1" colspan="1">&#x02212;<italic>2.619 </italic></td></tr><tr><td align="left" rowspan="1" colspan="1">84679</td><td align="center" rowspan="1" colspan="1">SLC9A7</td><td align="left" rowspan="1" colspan="1">Solute carrier family 9 (sodium/hydrogen exchanger), member 7</td><td align="center" rowspan="1" colspan="1">&#x02212;<italic>3.347 </italic></td><td align="center" rowspan="1" colspan="1">&#x02212;<italic>3.935 </italic></td></tr><tr><td align="left" rowspan="1" colspan="1">10599</td><td align="center" rowspan="1" colspan="1">SLCO1B1</td><td align="left" rowspan="1" colspan="1">Solute carrier organic anion transporter family, member 1B1</td><td align="center" rowspan="1" colspan="1">&#x02212;<italic>3.360 </italic></td><td align="center" rowspan="1" colspan="1">&#x02212;<italic>3.977 </italic></td></tr><tr><td align="left" rowspan="1" colspan="1">28234</td><td align="center" rowspan="1" colspan="1">SLCO1B3</td><td align="left" rowspan="1" colspan="1">Solute carrier organic anion transporter family, member 1B3</td><td align="center" rowspan="1" colspan="1">&#x02212;<italic>9.760 </italic></td><td align="center" rowspan="1" colspan="1">&#x02212;<italic>9.569 </italic></td></tr><tr><td align="left" rowspan="1" colspan="1">6578</td><td align="center" rowspan="1" colspan="1">SLCO2A1</td><td align="left" rowspan="1" colspan="1">Solute carrier organic anion transporter family, member 2A1</td><td align="center" rowspan="1" colspan="1">&#x02212;<italic>2.432 </italic></td><td align="center" rowspan="1" colspan="1">&#x02212;<italic>3.096 </italic></td></tr><tr><td align="left" rowspan="1" colspan="1">28232</td><td align="center" rowspan="1" colspan="1">SLCO3A1</td><td align="left" rowspan="1" colspan="1">Solute carrier organic anion transporter family, member 3A1</td><td align="center" rowspan="1" colspan="1">
<bold>&#x02212;2.032</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>&#x02212;2.152</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">353189</td><td align="center" rowspan="1" colspan="1">SLCO4C1</td><td align="left" rowspan="1" colspan="1">Solute carrier organic anion transporter family, member 4C1</td><td align="center" rowspan="1" colspan="1">
<bold>&#x02212;6.850</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>&#x02212;6.611</bold>
</td></tr></tbody></table></table-wrap><table-wrap id="tab3b" orientation="portrait" position="anchor"><caption><p>(b) Metabolism</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">Gene ID</th><th align="center" rowspan="2" colspan="1">Symbol</th><th align="left" rowspan="2" colspan="1">Name</th><th align="center" rowspan="1" colspan="1">Tumor bone</th><th align="center" rowspan="1" colspan="1">Tumor muscle</th></tr><tr><th align="center" rowspan="1" colspan="1">log<sub>2</sub>-fold change</th><th align="center" rowspan="1" colspan="1">log<sub>2</sub>-fold Cchange</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">1583</td><td align="center" rowspan="1" colspan="1">CYP11A1</td><td align="left" rowspan="1" colspan="1">Cytochrome P450, family 11, subfamily A, polypeptide 1</td><td align="center" rowspan="1" colspan="1">&#x02212;1.623</td><td align="center" rowspan="1" colspan="1">&#x02212;<italic>2.396 </italic></td></tr><tr><td align="left" rowspan="1" colspan="1">1589</td><td align="center" rowspan="1" colspan="1">CYP21A2</td><td align="left" rowspan="1" colspan="1">Cytochrome P450, family 21, subfamily A, polypeptide 2</td><td align="center" rowspan="1" colspan="1">&#x02212;1.962</td><td align="center" rowspan="1" colspan="1">
<bold>&#x02212;2.036</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">1591</td><td align="center" rowspan="1" colspan="1">CYP24A1</td><td align="left" rowspan="1" colspan="1">Cytochrome P450, family 24, subfamily A, polypeptide 1</td><td align="center" rowspan="1" colspan="1">&#x02212;<italic>5.208 </italic></td><td align="center" rowspan="1" colspan="1">&#x02212;<italic>5.577 </italic></td></tr><tr><td align="left" rowspan="1" colspan="1">1592</td><td align="center" rowspan="1" colspan="1">CYP26A1</td><td align="left" rowspan="1" colspan="1">Cytochrome P450, family 26, subfamily A, polypeptide 1</td><td align="center" rowspan="1" colspan="1">&#x02212;<italic>2.623 </italic></td><td align="center" rowspan="1" colspan="1">&#x02212;<italic>3.257 </italic></td></tr><tr><td align="left" rowspan="1" colspan="1">1594</td><td align="center" rowspan="1" colspan="1">CYP27B1</td><td align="left" rowspan="1" colspan="1">Cytochrome P450, family 27, subfamily B, polypeptide 1</td><td align="center" rowspan="1" colspan="1">&#x02212;1.846</td><td align="center" rowspan="1" colspan="1">&#x02212;<italic>2.585 </italic></td></tr><tr><td align="left" rowspan="1" colspan="1">339761</td><td align="center" rowspan="1" colspan="1">CYP27C1</td><td align="left" rowspan="1" colspan="1">Cytochrome P450, family 27, subfamily C, polypeptide 1</td><td align="center" rowspan="1" colspan="1">&#x02212;<italic>3.585 </italic></td><td align="center" rowspan="1" colspan="1">&#x02212;<italic>4.178 </italic></td></tr><tr><td align="left" rowspan="1" colspan="1">1553</td><td align="center" rowspan="1" colspan="1">CYP2A13</td><td align="left" rowspan="1" colspan="1">Cytochrome P450, family 2, subfamily A, polypeptide 13</td><td align="center" rowspan="1" colspan="1">&#x02212;1.962</td><td align="center" rowspan="1" colspan="1">
<bold>&#x02212;2.035</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">1580</td><td align="center" rowspan="1" colspan="1">CYP4B1</td><td align="left" rowspan="1" colspan="1">Cytochrome P450, family 4, subfamily B, polypeptide 1</td><td align="center" rowspan="1" colspan="1">
<bold>&#x02212;4.820</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>&#x02212;5.065</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">66002</td><td align="center" rowspan="1" colspan="1">CYP4F12</td><td align="left" rowspan="1" colspan="1">Cytochrome P450, family 4, subfamily F, polypeptide 12</td><td align="center" rowspan="1" colspan="1">
<bold>&#x02212;6.070</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>&#x02212;6.195</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">8529</td><td align="center" rowspan="1" colspan="1">CYP4F2</td><td align="left" rowspan="1" colspan="1">Cytochrome P450, family 4, subfamily F, polypeptide 2</td><td align="center" rowspan="1" colspan="1">
<bold>&#x02212;7.769</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>&#x02212;7.060</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">4051</td><td align="center" rowspan="1" colspan="1">CYP4F3</td><td align="left" rowspan="1" colspan="1">Cytochrome P450, family 4, subfamily F, polypeptide 3</td><td align="center" rowspan="1" colspan="1">
<bold>&#x02212;8.244</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>&#x02212;7.491</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">11283</td><td align="center" rowspan="1" colspan="1">CYP4F8</td><td align="left" rowspan="1" colspan="1">Cytochrome P450, family 4, subfamily F, polypeptide 8</td><td align="center" rowspan="1" colspan="1">
<bold>&#x02212;5.006</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>&#x02212;5.270</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">260293</td><td align="center" rowspan="1" colspan="1">CYP4X1</td><td align="left" rowspan="1" colspan="1">Cytochrome P450, family 4, subfamily X, polypeptide 1</td><td align="center" rowspan="1" colspan="1">
<bold>&#x02212;2.476</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>&#x02212;2.580</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">9420</td><td align="center" rowspan="1" colspan="1">CYP7B1</td><td align="left" rowspan="1" colspan="1">Cytochrome P450, family 7, subfamily B, polypeptide 1</td><td align="center" rowspan="1" colspan="1">&#x02212;<italic>2.502 </italic></td><td align="center" rowspan="1" colspan="1">&#x02212;<italic>3.170 </italic></td></tr><tr><td align="center" colspan="5" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="1" colspan="1">2326</td><td align="center" rowspan="1" colspan="1">FMO1</td><td align="left" rowspan="1" colspan="1">Flavin containing monooxygenase 1</td><td align="center" rowspan="1" colspan="1">&#x02212;<italic>4.360 </italic></td><td align="center" rowspan="1" colspan="1">&#x02212;<italic>4.859 </italic></td></tr><tr><td align="left" rowspan="1" colspan="1">2327</td><td align="center" rowspan="1" colspan="1">FMO2</td><td align="left" rowspan="1" colspan="1">Flavin containing monooxygenase 2 (nonfunctional)</td><td align="center" rowspan="1" colspan="1">
<bold>&#x02212;4.074</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>&#x02212;4.337</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">2328</td><td align="center" rowspan="1" colspan="1">FMO3</td><td align="left" rowspan="1" colspan="1">Flavin containing monooxygenase 3</td><td align="center" rowspan="1" colspan="1">
<bold>&#x02212;4.036</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>&#x02212;4.309</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">388714</td><td align="center" rowspan="1" colspan="1">FMO6P</td><td align="left" rowspan="1" colspan="1">Flavin containing monooxygenase 6 pseudogene</td><td align="center" rowspan="1" colspan="1">
<bold>&#x02212;2.569</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>&#x02212;2.737</bold>
</td></tr><tr><td align="center" colspan="5" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="1" colspan="1">493869</td><td align="center" rowspan="1" colspan="1">GPX8</td><td align="left" rowspan="1" colspan="1">Glutathione peroxidase 8 (putative)</td><td align="center" rowspan="1" colspan="1">&#x02212;<italic>2.814 </italic></td><td align="center" rowspan="1" colspan="1">&#x02212;<italic>3.371 </italic></td></tr><tr><td align="left" rowspan="1" colspan="1">2938</td><td align="center" rowspan="1" colspan="1">GSTA1</td><td align="left" rowspan="1" colspan="1">Glutathione S-transferase alpha 1</td><td align="center" rowspan="1" colspan="1">&#x02212;1.623</td><td align="center" rowspan="1" colspan="1">&#x02212;<italic>2.363 </italic></td></tr><tr><td align="left" rowspan="1" colspan="1">2939</td><td align="center" rowspan="1" colspan="1">GSTA2</td><td align="left" rowspan="1" colspan="1">Glutathione S-transferase alpha 2</td><td align="center" rowspan="1" colspan="1">&#x02212;<italic>2.038 </italic></td><td align="center" rowspan="1" colspan="1">&#x02212;<italic>2.741 </italic></td></tr><tr><td align="left" rowspan="1" colspan="1">2941</td><td align="center" rowspan="1" colspan="1">GSTA4</td><td align="left" rowspan="1" colspan="1">Glutathione S-transferase alpha 4</td><td align="center" rowspan="1" colspan="1">&#x02212;1.492</td><td align="center" rowspan="1" colspan="1">&#x02212;<italic>2.188 </italic></td></tr><tr><td align="left" rowspan="1" colspan="1">2953</td><td align="center" rowspan="1" colspan="1">GSTT2</td><td align="left" rowspan="1" colspan="1">Glutathione S-transferase theta 2</td><td align="center" rowspan="1" colspan="1">&#x02212;<italic>4.682 </italic></td><td align="center" rowspan="1" colspan="1">&#x02212;<italic>5.170 </italic></td></tr><tr><td align="left" rowspan="1" colspan="1">653689</td><td align="center" rowspan="1" colspan="1">GSTT2B</td><td align="left" rowspan="1" colspan="1">Glutathione S-transferase theta 2B (gene/pseudogene)</td><td align="center" rowspan="1" colspan="1">&#x02212;<italic>3.739 </italic></td><td align="center" rowspan="1" colspan="1">&#x02212;<italic>4.307 </italic></td></tr><tr><td align="center" colspan="5" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="1" colspan="1">84779</td><td align="center" rowspan="1" colspan="1">NAA11</td><td align="left" rowspan="1" colspan="1">N(alpha)-acetyltransferase 11, NatA catalytic subunit</td><td align="center" rowspan="1" colspan="1">&#x02212;<italic>7.439 </italic></td><td align="center" rowspan="1" colspan="1">&#x02212;<italic>7.996 </italic></td></tr><tr><td align="left" rowspan="1" colspan="1">9027</td><td align="center" rowspan="1" colspan="1">NAT8</td><td align="left" rowspan="1" colspan="1">N-acetyltransferase 8 (GCN5-related, putative)</td><td align="center" rowspan="1" colspan="1">
<bold>&#x02212;2.769</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>&#x02212;2.920</bold>
</td></tr><tr><td align="center" colspan="5" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="1" colspan="1">7358</td><td align="center" rowspan="1" colspan="1">UGDH</td><td align="left" rowspan="1" colspan="1">UDP-glucose 6-dehydrogenase</td><td align="center" rowspan="1" colspan="1">&#x02212;<italic>2.333 </italic></td><td align="center" rowspan="1" colspan="1">&#x02212;<italic>3.018 </italic></td></tr><tr><td align="left" rowspan="1" colspan="1">55757</td><td align="center" rowspan="1" colspan="1">UGGT2</td><td align="left" rowspan="1" colspan="1">UDP-glucose glycoprotein glucosyltransferase 2</td><td align="center" rowspan="1" colspan="1">&#x02212;1.604</td><td align="center" rowspan="1" colspan="1">&#x02212;<italic>2.271 </italic></td></tr><tr><td align="left" rowspan="1" colspan="1">10720</td><td align="center" rowspan="1" colspan="1">UGT2B11</td><td align="left" rowspan="1" colspan="1">UDP glucuronosyltransferase 2 family, polypeptide B11</td><td align="center" rowspan="1" colspan="1">
<bold>&#x02212;3.586</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>&#x02212;3.768</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">7367</td><td align="center" rowspan="1" colspan="1">UGT2B17</td><td align="left" rowspan="1" colspan="1">UDP glucuronosyltransferase 2 family, polypeptide B17</td><td align="center" rowspan="1" colspan="1">
<bold>&#x02212;2.836</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>&#x02212;2.959</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">54490</td><td align="center" rowspan="1" colspan="1">UGT2B28</td><td align="left" rowspan="1" colspan="1">UDP glucuronosyltransferase 2 family, polypeptide B28</td><td align="center" rowspan="1" colspan="1">
<bold>&#x02212;3.132</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>&#x02212;3.284</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">167127</td><td align="center" rowspan="1" colspan="1">UGT3A2</td><td align="left" rowspan="1" colspan="1">UDP glycosyltransferase 3 family, polypeptide A2</td><td align="center" rowspan="1" colspan="1">
<bold>&#x02212;4.716</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>&#x02212;4.907</bold>
</td></tr></tbody></table></table-wrap></table-wrap-group><table-wrap id="tab4" orientation="portrait" position="float"><label>Table 4</label><caption><p>FAF1 mutations in various cancers. FAF1 mutations listed in the TCGA data base were identified without restriction to any type of cancer. For the location of the affected domains on the protein compare <xref ref-type="fig" rid="fig2">Figure 2</xref>.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">AA</th><th align="center" rowspan="1" colspan="1">Mutation</th><th align="left" rowspan="1" colspan="1">Cancer</th><th align="center" rowspan="1" colspan="1">Domain</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">N4S</td><td align="center" rowspan="1" colspan="1">Missense</td><td align="left" rowspan="1" colspan="1">Cutaneous melanoma</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">I10S</td><td align="center" rowspan="1" colspan="1">Missense</td><td align="left" rowspan="1" colspan="1">Stomach adenocarcinoma</td><td align="center" rowspan="1" colspan="1">UBA</td></tr><tr><td align="left" rowspan="1" colspan="1">E21<sup>*</sup></td><td align="center" rowspan="1" colspan="1">Nonsense</td><td align="left" rowspan="1" colspan="1">Cutaneous melanoma</td><td align="center" rowspan="1" colspan="1">UBA</td></tr><tr><td align="left" rowspan="1" colspan="1">E25K</td><td align="center" rowspan="1" colspan="1">Missense</td><td align="left" rowspan="1" colspan="1">Uterine endometrioid carcinoma</td><td align="center" rowspan="1" colspan="1">UBA</td></tr><tr><td align="left" rowspan="1" colspan="1">V38_splice</td><td align="center" rowspan="1" colspan="1">Splice</td><td align="left" rowspan="1" colspan="1">Stomach adenocarcinoma</td><td align="center" rowspan="1" colspan="1">UBA</td></tr><tr><td align="left" rowspan="1" colspan="1">P86fs</td><td align="center" rowspan="1" colspan="1">FS del</td><td align="left" rowspan="1" colspan="1">Colorectal adenocarcinoma</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">G123_splice</td><td align="center" rowspan="1" colspan="1">Splice</td><td align="left" rowspan="1" colspan="1">Uterine endometrioid carcinoma</td><td align="center" rowspan="1" colspan="1">UB1</td></tr><tr><td align="left" rowspan="1" colspan="1">P136H</td><td align="center" rowspan="1" colspan="1">Missense</td><td align="left" rowspan="1" colspan="1">Colorectal adenocarcinoma</td><td align="center" rowspan="1" colspan="1">UB1</td></tr><tr><td align="left" rowspan="1" colspan="1">T147M</td><td align="center" rowspan="1" colspan="1">Missense</td><td align="left" rowspan="1" colspan="1">Brain lower grade glioma</td><td align="center" rowspan="1" colspan="1">UB1</td></tr><tr><td align="left" rowspan="1" colspan="1">D149Y</td><td align="center" rowspan="1" colspan="1">Missense</td><td align="left" rowspan="1" colspan="1">Uterine endometrioid carcinoma</td><td align="center" rowspan="1" colspan="1">UB1</td></tr><tr><td align="left" rowspan="1" colspan="1">L159V</td><td align="center" rowspan="1" colspan="1">Missense</td><td align="left" rowspan="1" colspan="1">Lung adenocarcinoma</td><td align="center" rowspan="1" colspan="1">UB1</td></tr><tr><td align="left" rowspan="1" colspan="1">K163N</td><td align="center" rowspan="1" colspan="1">Missense</td><td align="left" rowspan="1" colspan="1">Uterine endometrioid carcinoma</td><td align="center" rowspan="1" colspan="1">UB1</td></tr><tr><td align="left" rowspan="1" colspan="1">L170F</td><td align="center" rowspan="1" colspan="1">Missense</td><td align="left" rowspan="1" colspan="1">Cutaneous melanoma</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">G184_splice</td><td align="center" rowspan="1" colspan="1">Splice</td><td align="left" rowspan="1" colspan="1">Colorectal cancer</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">Q187H</td><td align="center" rowspan="1" colspan="1">Missense</td><td align="left" rowspan="1" colspan="1">Stomach adenocarcinoma</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">S214N</td><td align="center" rowspan="1" colspan="1">Missense</td><td align="left" rowspan="1" colspan="1">Colorectal adenocarcinoma</td><td align="center" rowspan="1" colspan="1">UB2</td></tr><tr><td align="left" rowspan="1" colspan="1">R222I</td><td align="center" rowspan="1" colspan="1">Missense</td><td align="left" rowspan="1" colspan="1">Uterine endometrioid carcinoma</td><td align="center" rowspan="1" colspan="1">UB2</td></tr><tr><td align="left" rowspan="1" colspan="1">E238D</td><td align="center" rowspan="1" colspan="1">Missense</td><td align="left" rowspan="1" colspan="1">Lung adenocarcinoma</td><td align="center" rowspan="1" colspan="1">UB2</td></tr><tr><td align="left" rowspan="1" colspan="1">P241S</td><td align="center" rowspan="1" colspan="1">Missense</td><td align="left" rowspan="1" colspan="1">Uterine endometrioid carcinoma</td><td align="center" rowspan="1" colspan="1">UB2</td></tr><tr><td align="left" rowspan="1" colspan="1">T245A</td><td align="center" rowspan="1" colspan="1">Missense</td><td align="left" rowspan="1" colspan="1">Renal clear cell carcinoma</td><td align="center" rowspan="1" colspan="1">UB2</td></tr><tr><td align="left" rowspan="1" colspan="1">M249V</td><td align="center" rowspan="1" colspan="1">Missense</td><td align="left" rowspan="1" colspan="1">Uterine endometrioid carcinoma</td><td align="center" rowspan="1" colspan="1">UB2</td></tr><tr><td align="left" rowspan="1" colspan="1">E280K</td><td align="center" rowspan="1" colspan="1">Missense</td><td align="left" rowspan="1" colspan="1">Brain lower grade glioma</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">G293<sup>*</sup></td><td align="center" rowspan="1" colspan="1">Nonsense</td><td align="left" rowspan="1" colspan="1">Colorectal cancer</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">T300I</td><td align="center" rowspan="1" colspan="1">Missense</td><td align="left" rowspan="1" colspan="1">Colorectal adenocarcinoma</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">D305H</td><td align="center" rowspan="1" colspan="1">Missense</td><td align="left" rowspan="1" colspan="1">Lung adenocarcinoma</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">E308Q</td><td align="center" rowspan="1" colspan="1">Missense</td><td align="left" rowspan="1" colspan="1">Lung adenocarcinoma</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">A316V</td><td align="center" rowspan="1" colspan="1">Missense</td><td align="left" rowspan="1" colspan="1">Stomach adenocarcinoma</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">K319fs</td><td align="center" rowspan="1" colspan="1">FS ins</td><td align="left" rowspan="1" colspan="1">Head and neck squamous cell carcinoma</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">R344G</td><td align="center" rowspan="1" colspan="1">Missense</td><td align="left" rowspan="1" colspan="1">Stomach adenocarcinoma</td><td align="center" rowspan="1" colspan="1">UAS</td></tr><tr><td align="left" rowspan="1" colspan="1">F353I</td><td align="center" rowspan="1" colspan="1">Missense</td><td align="left" rowspan="1" colspan="1">Cutaneous melanoma</td><td align="center" rowspan="1" colspan="1">UAS</td></tr><tr><td align="left" rowspan="1" colspan="1">L379V</td><td align="center" rowspan="1" colspan="1">Missense</td><td align="left" rowspan="1" colspan="1">Breast invasive carcinoma</td><td align="center" rowspan="1" colspan="1">UAS</td></tr><tr><td align="left" rowspan="1" colspan="1">C396F</td><td align="center" rowspan="1" colspan="1">Missense</td><td align="left" rowspan="1" colspan="1">Cutaneous melanoma</td><td align="center" rowspan="1" colspan="1">UAS</td></tr><tr><td align="left" rowspan="1" colspan="1">S459<sup>*</sup></td><td align="center" rowspan="1" colspan="1">Nonsense</td><td align="left" rowspan="1" colspan="1">Uterine endometrioid carcinoma</td><td align="center" rowspan="1" colspan="1">UAS</td></tr><tr><td align="left" rowspan="1" colspan="1">G469_splice</td><td align="center" rowspan="1" colspan="1">Splice</td><td align="left" rowspan="1" colspan="1">Glioblastoma multiforme</td><td align="center" rowspan="1" colspan="1">UAS</td></tr><tr><td align="left" rowspan="1" colspan="1">R509G</td><td align="center" rowspan="1" colspan="1">Missense</td><td align="left" rowspan="1" colspan="1">Lung squamous cell carcinoma</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">E510fs</td><td align="center" rowspan="1" colspan="1">FS del</td><td align="left" rowspan="1" colspan="1">Cutaneous melanoma</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">R516C</td><td align="center" rowspan="1" colspan="1">Missense</td><td align="left" rowspan="1" colspan="1">Uterine endometrioid carcinoma</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">A534V</td><td align="center" rowspan="1" colspan="1">Missense</td><td align="left" rowspan="1" colspan="1">Stomach adenocarcinoma</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">F537L</td><td align="center" rowspan="1" colspan="1">Missense</td><td align="left" rowspan="1" colspan="1">Stomach adenocarcinoma</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">E551<sup>*</sup></td><td align="center" rowspan="1" colspan="1">Nonsense</td><td align="left" rowspan="1" colspan="1">Lung adenocarcinoma</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">R554W</td><td align="center" rowspan="1" colspan="1">Missense</td><td align="left" rowspan="1" colspan="1">Colorectal cancer</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">S582I</td><td align="center" rowspan="1" colspan="1">Missense</td><td align="left" rowspan="1" colspan="1">Lung adenocarcinoma</td><td align="center" rowspan="1" colspan="1">UBX</td></tr><tr><td align="left" rowspan="1" colspan="1">F585L</td><td align="center" rowspan="1" colspan="1">Missense</td><td align="left" rowspan="1" colspan="1">Uterine endometrioid carcinoma</td><td align="center" rowspan="1" colspan="1">UBX</td></tr><tr><td align="left" rowspan="1" colspan="1">E587<sup>*</sup></td><td align="center" rowspan="1" colspan="1">Nonsense</td><td align="left" rowspan="1" colspan="1">Lung adenocarcinoma</td><td align="center" rowspan="1" colspan="1">UBX</td></tr><tr><td align="left" rowspan="1" colspan="1">A592V</td><td align="center" rowspan="1" colspan="1">Missense</td><td align="left" rowspan="1" colspan="1">Stomach adenocarcinoma</td><td align="center" rowspan="1" colspan="1">UBX</td></tr><tr><td align="left" rowspan="1" colspan="1">W610<sup>*</sup></td><td align="center" rowspan="1" colspan="1">Nonsense</td><td align="left" rowspan="1" colspan="1">Breast invasive carcinoma</td><td align="center" rowspan="1" colspan="1">UBX</td></tr><tr><td align="left" rowspan="1" colspan="1">D611Y</td><td align="center" rowspan="1" colspan="1">Missense</td><td align="left" rowspan="1" colspan="1">Lung adenocarcinoma</td><td align="center" rowspan="1" colspan="1">UBX</td></tr><tr><td align="left" rowspan="1" colspan="1">E635fs</td><td align="center" rowspan="1" colspan="1">FS del</td><td align="left" rowspan="1" colspan="1">Brain lower grade glioma</td><td align="center" rowspan="1" colspan="1">UBX</td></tr><tr><td align="left" rowspan="1" colspan="1">P640fs</td><td align="center" rowspan="1" colspan="1">FS del</td><td align="left" rowspan="1" colspan="1">Cutaneous melanoma</td><td align="center" rowspan="1" colspan="1">UBX</td></tr></tbody></table></table-wrap></floats-group></article>